

TITLE PAGE:

MINIREVIEW:

**PORCINE PREDICTION OF PHARMACOKINETIC PARAMETERS IN PEOPLE: A
PIG IN A POKE?**

Huadong Tang and Michael Mayersohn

Guangzhou Dazhou Biomedicine Ltd (H.T.; M.M.); Department of Pharmacy Practice
and Science, College of Pharmacy, The University of Arizona, Tucson, AZ (M.M.)

RUNNING TITLE PAGE:

Running Title: Porcine Prediction of Pharmacokinetics in People

Guangzhou Dazhou Biomedicine (GDB) Ltd, Building B, Qirui Science-Technology
Park, Nanxiang 2nd Rd, Guangzhou, China

huadong.tang@dazhoubiomed.com

number of text pages: 44

number of tables: 3 (2 in Appendix)

number of figures: 4

number of references: 133 (text); 65 (Appendix)

number of words in Abstract: 250

number of words in Introduction: 1059

number of words in Discussion: 10,441

number of words in Summary and Conclusions: 183

number of words in acknowledgements: 95

Abbreviations:

AAFE, absolute average fold-error; AUC, area under the plasma concentration-time curve; BrW, brain weight; CL_{int}, intrinsic clearance; C_{max}, maximum plasma concentration; CYP, cytochrome P-450; f_{up}, fraction unbound in plasma; F, fraction of the dose systemically available; GIT, gastrointestinal tract; IVIVC, *in vitro-in vivo* correlation; IVIVE, *in vitro-in vivo* extrapolation; MLP, maximum life span potential; PK, pharmacokinetics; ROE, rule of exponents ; T_{max}, time of occurrence of maximum plasma concentration.

ABSTRACT:

The minipig has become an animal of considerable interest in preclinical drug development. It has been used in toxicology research and in examining/establishing regulatory guidelines as a non-rodent animal model. We have reviewed some basic issues that one would want to consider in the development and testing of any animal model for humans. The pig is a reasonable alternative to the dog, but there are some clear limitations and unexplained disparities in the literature, which require further study, primary among these is the need for standardization in choice of breed and sex and routine protocols. The minipig offers numerous advantages over other established animal models and it has similarities to the human with regard to anatomy, physiology and biochemistry. The gastrointestinal tract is structurally and functionally similar to humans. This appears to be true for enzymes and transporters in the gut as well, but more study is needed. One major concern is assessment of oral drug absorption, especially with regard to potential food-effects due to gastric emptying differences, yet this does not appear to be a consistent observation. Hepatic metabolism seems to reflect enzymatic patterns in humans, with some differences. Kidney function seems similar to humans but requires further study. We have analyzed literature data that suggest the pig would offer a reasonable model for human oral bioavailability and for allometric predictions of clearance. The minipig appears to be the model for dermal absorption in humans and we discuss this in terms of literature data and our own in-house experience.

Introduction and Historical Perspective

Modern breeds of swine (hog, pig) are derived from wild boar, *Sus scrofa*, which were domesticated about 10,000 years ago in the Middle East, about 7,000 years ago in East Asia and later in Europe (Ganderup, 2016). There are early references to the use of pigs in medical research, especially in physiological and anatomical investigations by such historical luminaries as Galen (130-200 AD), Harvey (ca., 1628) and Bernard (ca., 1865) (Bollen *et al.*, 2010). While the pig has become an invaluable animal model for a wide variety of biomedical research investigations, the farm pig is generally not suitable for such purposes because of its size, rapid growth and lack of control of a safe and healthy environment from the time of birth. Many authors cite to the similarities between pigs and humans with regard to anatomical, physiological and biochemical characteristics (Doyle *et al.*, 1968; Swindle and Smith, 1998). Among these similarities are included: cardiovascular system; gastrointestinal tract; liver; adrenals; skin and kidney. In recognition of the remarkable and numerous similarities between the pig and humans, there was a concerted effort, beginning in the late 1940s, to develop small strains of the species to accommodate the needs of experimental medical and biological research. The Hormel minipig was first bred in 1949 (Hormel Institute, Austin, MN) and from it were derived several popular breeds including the Göttingen (ca., 1961) and Sinclair minipigs (ca., 1965), which belong to the smaller weight minipigs along with the Yucatan micropig (*i.e.*, 35-70 kg mature weight). The Hanford and Yucatan (ca., 1960) minipigs have larger adult weights (ca., 70-90 kg) (Bollen *et al.*, 2010). Although there are numerous other minipig breeds (*e.g.*, Vietnamese potbelly), the most popular breeds have been the

Göttingen, Yucatan, Hanford and Sinclair. In contrasting numerous biological metrics, Bollen *et al.* (2010) list “miniature” swine having two categories; 35-70 kg and 70-90 kg, as noted above. The term “micro-pig” seems to be of recent vintage and appears to refer to animals less than about 35 kg; however, we have not found a working definition.

Doyle *et al.* (1968) summarized various aspects of and comparisons among domesticated farm animals for use in medical research and notes the greater interest in selecting an animal model on the basis of its similarity to humans or because of a specific feature related to the human medical or disease condition (*i.e.*, “pathological appropriateness”). The pig is similar to humans with regard to, at least, the nervous and cardiovascular systems and the gastrointestinal tract (GIT) (Earl *et al.*, 1964) and others have noted that the pig is the accepted model for human dermal studies (*e.g.*, “The minipig is the species of choice to investigate dermal absorption in preclinical drug development.”; Preube and Skaanild (2012)). While the GIT blood circulation in the chimpanzee is quite similar to that of humans, Noer (1943) has noted that the circulation in the small intestine of the dog is quite different from humans. Importantly, there has been an extensive accumulation of biological data in farm animals over many years, which provides useful basic information relevant to the choice of animal models.

Driven in part by regulatory agencies requiring the use of a rodent and non-rodent model for a wide range of testing prior to submission of new chemical entities (NCE) to inform the design of safe clinical studies as well as support the safety evaluation included in the regulatory registration of new drugs and chemicals. There has been interest in non-rodent species other than the dog, which has more or less become the default animal species of choice; somewhat surprising as it is a popular companion animal. Other

species having a closer genetic relationship to humans, especially primates, such as the monkey and chimpanzee, while possibly offering the greatest potential similarity to humans, have significant disadvantages including ethical and cost issues. The pig, especially the minipig and micropig, offer significant advantages as a non-rodent model for all phases of drug testing, from early preclinical studies to toxicology investigations (e.g., Svendsen, 1997) and food additives and medical device testing; indeed, the minipig appears to have become the standard animal model for toxicology studies in Western Europe. Among these advantages are: similarities to humans in numerous body systems with regard to anatomy, physiology and biochemistry; small size and docile characteristics; ease of breeding; long-term study (cross-over designs) and sampling; all dosing routes used in humans are accessible in pigs; not generally considered a companion animal. The pig is generally regarded as the animal of choice for xenotransplantation and it is rapidly becoming so for human risk assessment and, we predict, for preclinical drug studies (Walters *et al.*, 2011).

An attempt will be made to review, in a limited way, our current state of knowledge with regard to the role of minipigs in biomedical research, especially with respect to drug development and testing issues and use as a species for predicting human drug behavior and disposition. To the extent possible, given space limitations, we will attempt to summarize and reinterpret/re-analyze the literature (where necessary), highlight the current status and utility and offer commentary on limitations of our understanding and future directions. As noted by Box (1976, 1979), with regard to statistical models, “All models are wrong, but some are useful”; we strongly believe that the same admonition

applies to animal models used for the purposes of describing and predicting drug disposition and behavior in humans.

Some relevant general reference texts to which the interested reader might want to refer (including some cited above), include: Bustad *et al.* (1966); Swindle (1983, 1992, 1998); Tumbleson (1986); Tumbleson and Schook (1996); Pond and Mersmann (2001); Bollen *et al.* (2010); McAnulty *et al.* (2012); Swindle and Smith (2016). There are also several reviews comparing minipigs and humans in terms of drug testing and pharmacokinetics (e.g., Witkamp and Monshouwer, 1998; van der Laan *et al.*, 2010; Lignet *et al.*, 2016). Furthermore, reflecting the interest in the pig as a useful animal model, the NIH maintains a National Swine Resource and Research Center, established in 2003 (www.nsrrc.missouri.edu). The stated purpose of the Center is, “..to develop the infrastructure to ensure that biomedical investigators across a variety of disciplines have access to critically needed swine models of human health and disease.” More recently a “Pig PeptideAtlas”, has been made available, a resource for proteome research (Hesselager *et al.*, 2016).

Physiological and anatomical considerations

Swindle and Smith (1998) have provided a relatively short review of the comparative anatomy and physiology of the pig. More in-depth reviews of specific body systems in the pig can be found in McAnulty *et al.* (2012). As with any other animal model, the pig is not a duplicate of the human (and, hence, a “model”), but it appears to share substantial similarities with humans with regard to certain, but not all, body systems. Differences are expected to exist; the degree of those differences and their expected

impact on the function of interest is what determines the model's potential limitation. The **cardiovascular system** is sufficiently similar to that of the pig that it is considered a standard model for purposes of drug and device testing and for studies of the diseased heart (e.g., Swindle and Smith, 1998; Gootman, 2001; Myers *et al.*, 2016). Differences, however, do exist and need to be considered (Bode *et al.*, 2010). The **gastrointestinal tract**, an essential system to consider for oral drug absorption and bioavailability studies as well as for pre-clinical experiments involving the oral route, is physiologically similar to the human GIT, but there are some important anatomical differences. Kararli (1995) has provided a useful compilation comparing aspects of the GIT among commonly used laboratory animals, including the pig. The buccal epithelium of the pig is similar to that of humans and absorption from the buccal cavity has been examined in numerous studies (e.g., Meng-Lund *et al.*, 2016). Pigs are true omnivores, unlike rodents, rabbits and carnivores and it is that behavior that may result in shared similar physiological functions. While able to vomit, the pig is less prone to emesis than the dog, an advantage following oral drug dosing (Bode *et al.*, 2010). The GIT in the pig differs in several ways from that in the human. The presence of a pharyngeal diverticulum needs to be considered when oral gavage tubes are placed to avoid problems upon intubation. While the stomach has the same basic shape and regions (and function) as in humans, there is a muscular pouch (torus pyloricus) near the pyloric sphincter, which facilitates the closure of the pylorus. The adult Yucatan (*ca.*, 50 kg) stomach volume is about 1300 mL. The primary secretory cells include: mucous, parietal (HCl secretion) and chief (protease secretion; primarily pepsin) cells. Gastric fluid pH ranges from 1.6-4.3; mean liquid retention time, 0.8-0.9 hours; mean solid retention time, 1.0-1.3 hours; half-emptying time (semi-solids), 0.75-

0.96 hours (Van Ginneken, 2012). Others have suggested an emptying time of 2-8 hours, depending on several variables; or 2-4 hours if fasting before measurement (Casteel *et al.*, 1998). Because of its potential importance in drug absorption, the literature concerning gastric emptying is discussed more completely in a later section.

The long (as in humans) small intestine is located primarily on the right side of the abdomen. The duodenum, jejunum and ileum occupy about 5%, 90% and 5%, of the small intestine, respectively, with a diameter of about 20 mm in a 50 kg Yucatan pig (McCrackin and Swindle, 2016). The human colon exists in an inverted U-shape to accommodate the ascending, transverse and descending colon. In contrast the pig large intestine is tightly coiled (“spiral colon”) and is located in the left upper quadrant of the abdomen. The large intestine is about 20% the length of the small intestine with a diameter of about 25 mm. The total estimated surface area of the small intestine in the pig (47 kg) ranges from 168-210 m² (vs. 252 m² in a 70 kg human) (DeSesso and Williams, 2008). Total blood flow to the GIT is estimated to be 22% of cardiac output in the Yucatan pig (McKirnan *et al.*, 1991); comparable to humans. Descriptions of the small intestine and colon indicate essentially the same physiological and biochemical functions to those of humans. These organs are designed to secrete biochemicals, process food and provide efficient absorption of digested materials, just as in humans and other mammals. The small intestinal fluid pH ranges from 5.7-7.2; mean liquid retention time, 3.9-4.4 hours; mean solid retention time, 3.7-4.3 hours. The colon has a fluid pH of about 7.1; mean liquid retention time, 24.9-41.3 hours; mean solid retention time, 35.6-44.4 hours (Van Ginneken, 2012). Most of these numerical values are similar to those measured and reported in humans, although the colonic retention times in the pig seem

quite long. pH ranges noted above are those most often cited for human gastric and intestinal fluids. Intestinal transit times in humans is generally considered to be about 4 hours, regardless of the presence or absence of food. The presence of metabolizing enzyme systems and transporters in the gut wall is discussed later.

Swindle (2016) notes the similarity of the pig and human **liver** from a surgical perspective, however, the pig's liver is made up of six lobes and a gall bladder, compared to the four lobes in a human liver. The liver, from a functional, physiological and biochemical standpoint, is comparable between the two species. Indeed, the pig is the most often cited source of liver cells when considering an engineered pig-derived liver for transplantation into humans or an extracorporeal device (e.g., Schuurman *et al.*, 2012). Similar considerations apply to numerous other engineered pig-derived organs (Waltz, 2017). Composition of pig bile is similar to that of most mammals, with the exception of having less cholic acid and a bile salt: phospholipid concentration of 9:1 (Swindle, 1996). Total hepatic blood flow in the chronically catheterized conscious farm pigs (8-16 weeks; 20-70 kg) was determined to be about 1100 mL/min (ca., 20-25% of cardiac output), a value essentially the same as in adult humans (Drougas *et al.*, 1996). An important consideration is that the porcine liver is more similar to the human liver than most other species with regard to enzymatic metabolic potential (Swindle, 1996). An extensive listing of cytochrome (CYP) P450 liver enzymes can be found in Preube and Skaanild (2012). Total liver microsome CYP P450 in Göttingen minipigs (ca., 0.81 nmol/mg protein) is higher than estimates in Caucasians (ca., 0.43 nmol/mg protein). While the pig liver has essentially the entire complement of CYP P450 isozymes, with some exceptions (e.g., low CYP2C (Puccinelli *et al.*, 2011) and high CYP2D (Thorn *et al.*, 2011)), one needs to

be aware of differences among farm pigs and breeds of mini-pigs and between males and females. Bode *et al.* (2010) conclude, “All main metabolic activities typical for human CYP enzymes are found in porcine liver microsomes (Anzenbacher *et al.*, 1998; Monshouwer *et al.*, 1998; Skaanild and Friis, 1997).” Preube and Skaanild (2012) have presented a useful and extensive comparative table of CYP450s found in the liver of humans and pigs. The readers are referred to that source for specific comparisons. Phase II metabolism has not been thoroughly studied to date. One report indicates that liver microsomes of the Yucatan minipig are able to glucuronidate nicotine and cotinine, while mice, rats, rabbits and dogs showed no such activity (Ghosheh and Hawes, 2002). More information about enzymes and transporters is provided in a later section.

The pig **kidney**, as with most mammals, is similar to that of the human in terms of function, physiology and anatomy. The kidney has been well characterized as a result of its use in transplantation surgery (Conn, 2008). Importantly, access to the male urinary tract is not possible as a result of the sigmoid flexure of the penis. Urine pHs, which can influence the excretion of ionizable drugs, encompass the same range in humans and pigs (ca., 7-9) depending on nutrition. Glomerular filtration rates in adult humans and pigs are essentially the same (ca., 126-175 mL/min in pigs vs. 130 mL/min in humans per 70 kg) as is renal blood flow, 3.0-4.4 mL/(min×g) in pigs vs. 4.0 mL/(min×g) in humans (Sachs, 1994).

Gastric emptying and intestinal transit

Gastric emptying (GE) is an important physiological variable that may impact drug absorption from the human GIT, as is well known in the field (e.g., Mayersohn, 2009). It

is not surprising that the same has been found in the pig, although there remains considerable lack of consensus about numerical values because of substantially different findings reported in the literature and, therefore, questions remain about the utility of the pig for oral absorption studies in the absence and presence of food. (Some caution here to the reader, values for GE in the literature are presented in different metrics: GE rate or rate constant, GE time, GE half-time.) During fasting, as in humans, GE is controlled by the migrating myoelectric complex (MMC). Numerous factors will affect emptying rate in the fed condition including, type and volume of meal, viscosity, osmolarity, *etc.*, as is the case in humans. It is important to note that the feeding pattern will have an important impact on GE. Small frequent meals do not appear to interfere with the MMC during the day; whereas, two large meals interrupt the MMC for about 6 hours and a fed pattern is seen (Argenzio and Monteiro-Riviere, 2001). Differences in feeding patterns may explain some of the disparity in the literature with regard to food effects on GE and drug absorption. GE of food follows a bimodal pattern; 30-40% empties within 15 minutes of eating with subsequent emptying during the next hour. However, emptying may be incomplete with food remaining in the stomach for the entire day (Witkamp and Monshouwer 1998). Davis *et al.* (2001) were among the first investigators to study GE and intestinal transit of pharmaceutical dosage forms in the pig (large white/Landrace/Duroc cross; 90-100 kg; fed twice a day) using external gamma scintigraphy. Animals were fasted for 18 hours prior to dosing and 6 hours following dosing. The mean emptying half-time for a test liquid and solid pellets were 1.4 hours and 2.2 hours, respectively. In three pigs tested, the time to complete emptying of a tablet was between 5-6 hours in two animals and 1.5-2 hours in another. Estimates of small intestinal

transit times were 3-4 hours and considerably longer time for total transit (*ca.*, 24-72 hours, with wide variability). These values appear to be consistent with those reported by other investigators (see Table 4 in Davis *et al.*, 2001), suggesting that the pig would be a good representative model of humans with regard to GE. In sharp contrast with these findings, however, are reports by other investigators who determined long and sometimes extraordinarily long GE times (Hossain *et al.*, 1990; Aoyagi *et al.*, 1992; Kabanda *et al.*, 1994), all of whom conclude that the pig is not a good model to assess drug absorption and bioavailability in humans. Prolonged gastric residence (>5 days) was found for enteric-coated non-disintegrating magnesium hydroxide caplets (Hossain *et al.*, 1990). Aoyagi *et al.* (1992) found that the dog is a better animal model for bioavailability studies under fasting conditions than the pig by examining GE among human, dog, pig and rabbit with non-digestible tablets and granules. Kabanda *et al.* (1994) also observed a long stomach residence time of erodible matrix tablets in pigs.

It is difficult to reconcile these disparities reported in GE, however, one notes experimental differences (*e.g.*, fed/fasted, frequency of feeding, type of food ingested, breed, sex and age/weight of animals, *etc.*) that could account for at least some of the differences measured. What is wanting here, clearly, as should be made obvious from this review in general, is standardization of procedures and, to the extent possible, choice of pig breed. More recent attempts to investigate this issue using, for example, acetaminophen as a marker compound for GE, have rather convincingly demonstrated, under the reported experimental conditions, that pigs have a prolonged GE, food remains in the stomach (even after fasting for many hours; confirmed by post-mortem inspection) and protocols to resolve this concern (*e.g.*, administration of GIT stimulants, such as

metoclopramide) may not be appropriate or always work (Suenderhauf *et al.*, 2014; Christiansen *et al.*, 2015; Henze *et al.*, 2018). Lack of a food-effect, when expected or noted in humans for specific drugs and not found in pigs, using the FDA-approved high-fat content meal (often used in the dog), would suggest that the pig is not, under current protocols, a reliable animal model.

Is the pig still a viable model for examining drug absorption, dosage form and route of administration effects? We believe, as do others, that the answer to this question is yes, with the qualification of the need for additional studies under well controlled conditions to establish standard protocols. Aspects of this issue will be discussed in several of the following sections.

Hepatic and GIT enzymatic metabolism and transporters

Substantial effort has been expended in attempts to characterize metabolizing enzymes in various body systems of the pig, especially the liver and GIT, with special interest in comparison with humans. Achour *et al.* (2011) conducted a thorough study of the cytochrome P450 liver enzyme system obtained from two pig livers (adult Suffolk White). (As an aside, this publication illustrates the extent to which the pig can be instrumented by conducting surgical procedures that are able to address complex questions of absorption and metabolism.) It is likely that the results can be generalized to minipig breeds, but further study may be required. The investigators identified the P450 subfamilies to be (% total P450): CYP 1A (2%), CYP2A (34%), CYP2C (16%), CYP2D (26%), CYP2E (8%) and CYP3A (14%). CYP3A is present in a larger percentage in human liver and is the major drug metabolizing enzyme and responsible for the majority

of drug-drug interactions. The investigators also found sequence homology between the pig and human P450 isoforms ranged from 72 to 95% with a similarity of about 98%. These findings are in agreement with numerous previous investigations using Göttingen minipig livers as the source of microsomes (e.g., Anzenbacher *et al.*, 1998), which leads to the general conclusion that the pig offers an excellent representation of the human liver complement of CYP450s (e.g., see reviews by Skaanild, 2006; Puccinelli *et al.*, 2011). Higher levels of FMO1 have been observed in the minipig liver microsomes compared to humans (Yamazaki *et al.*, 2014).

This general conclusion, however, should not imply the same identity, activity or substrate specificity to all human CYP isoforms. For example, Thorn *et al.* (2011) noted qualitative differences in the metabolite pattern of testosterone (3A4); whereas, diclofenac (CYP2C) metabolism was low in the pig, while dextromethorphan metabolism by CYP2D6 was extensive and rapid compared to the human isozyme. Verapamil, a 3A4 substrate, exhibited similar metabolism between pig and humans (Petri *et al.*, 2006). Similar observations were made by others; human CYP2C substrate, S-mephenytoin, was not metabolized by the pig; diclofenac and tolbutamide, also CYP2C substrates, were metabolized to a much lower extent in pigs (Puccinelli *et al.*, 2011; Anzenbacher *et al.*, 1998). Such differences help to explain deviations of predictions of metabolic clearance or estimates of oral bioavailability in humans based on the pig (see later section). Metabolic differences are further complicated by both breed of pig and sex. The Landrace pig has shown substantial CYP2D6 and CYP2C9 activity; whereas, the Göttingen breed exhibits minimal activity of those isoforms. The Göttingen minipig illustrates more sex-dependent enzyme activity than other breeds; CYP1A2 and CYP2E1 activity was about

4-times greater in the female vs. the male Göttingen and there was a 70-fold higher CYP2A activity in female compared to male minipigs, while similar activity was observed in Landrace pigs (Skaanild and Friis, 1997; Bogaards *et al.*, 2000). Similar differences are not seen in humans, which raises significant issues with regard to harmonization in developing the pig model to reflect the human condition. Any differences between the species in intrinsic hepatic clearance will affect hepatic extraction ratio and, therefore, the extent of the hepatic first-pass effect and systemic bioavailability. Bioavailability and prediction of species-based pharmacokinetic parameters are discussed in later sections.

There have been limited studies examining phase II metabolic processes. It seems that glucuronidation is greater, while sulfation is lower in the pig compared to humans (Nielsen and Dalgaard, 1978). Hepatic UDP-glucuronosyltransferase (UGT) has been found in minipigs and shown to glucuronidate numerous drugs similar to what is seen in humans (Higashi *et al.*, 2014). Acetylation (NAT1 and NAT2) has been observed in the pig, which is absent in the dog (Trepanier *et al.*, 1997; Loureiro *et al.*, 2013). Clearly, more in-depth study of phase II metabolism is called for, given the importance of conjugating enzymes in drug metabolism.

Aldehyde oxidase (AOX) is involved in metabolic processes of many drugs, including those containing heterocyclic nitrogen. While dogs lack hepatic AOX, pigs have been shown to have an active form (Diaz and Squires, 2000; Garattini and Terao, 2013). *In vitro-In vivo* extrapolation (IVIVE) of the clearance of substrates involved in the AOX metabolic pathway was studied in minipigs using AOX substrates. The results showed that *In vivo* clearance was under-predicted by IVIVE, generally similar to that observed for compounds with elimination mechanisms *via* other metabolic pathways. *In vivo*-based

allometry, with an exponent fixed at 0.75 (between minipigs and humans), seemed to predict well the human *in vivo* clearance, supporting the use of minipigs for predicting human PK for AOX substrates (Wilkinson *et al.*, 2017). The *in vitro* intrinsic clearances (CL_{int}) of five AOX substrates in multiple species, including humans and minipigs, were evaluated. An allometric model of *in vitro* CL_{int} was examined using single (exponent fixed at 0.75) or multiple species. The single-species method seemed to predict the human *in vitro* CL_{int} reasonably well. It should be noted that the prediction of the *in vivo* human clearance still needs determination of whether the IVIVE within species is predictive. Nevertheless, the allometric model for the *in vitro* CL_{int} demonstrated a good correlation of CL_{int} for AOX-based metabolism (Crouch *et al.*, 2018).

Enzyme-mediated hydrolysis reactions represent an important metabolic route for, as an example, prodrugs (often esters) that require hydrolysis prior to or after reaching the systemic circulation following oral, transmucosal or transdermal administration. Relatively little information is available about these reactions in the pig, although they have been widely studied in humans. Important among these enzymes is the carboxylesterase family. DDAO benzoate, which is a specific probe for human carboxylesterase 2 was shown to have higher activity in pig liver microsomes compared to humans and dogs (Ma *et al.*, 2017). Minipig skin appears to be similar to human skin with regard to ester hydrolysis of dermally applied drugs (Jewell *et al.*, 2007; Prusakiewicz *et al.*, 2006); observations further supporting the pig as a model for dermal drug absorption is discussed later. *In vivo* studies, corresponding to these *in vitro* studies need to be conducted and the resulting correlation established in order to fully understand and quantitatively use the pig as a model for compounds undergoing enzymatic hydrolysis.

Jones *et al.* (2016) present a strategy to identify drugs which may not be suited for study in the minipig because of excessive amide hydrolysis.

An additional aspect of presystemic metabolism involves GIT first-pass effects. The GIT is the most important extrahepatic site of drug metabolism (Helke and Swindle, 2013). A further complication is that of influx and efflux transporters in the small intestine, which work in tandem with GIT enzymes. Quantitative information about metabolizing enzymes in the GIT of the pig appears sparse, although CYP 3A has been shown in the small intestine of the developing Göttingen breed along with the presence of P-gp (Peer, 2014). Shulman *et al.* (1988) have suggested that the young minipig (Hanford) reflects the GIT membrane content of selected enzymes (lactase, sucrase, maltase, glucoamylase and acid β -galactosidase) in the human infant and, therefore, would be a useful model in pediatric GIT research. Tang *et al.* (2004) examined the distribution pattern of P-gp protein levels along the entire GIT of the Yucatan micropig. The amount of P-gp protein increased distally from the duodenum to the ileum over an approximate 10-fold range with much lower amounts in the colon. This expression pattern is similar to that reported in humans (Mouley and Paine, 2003). It is noted that the intestinal permeability using the pig model was studied by Westerhout *et al.* (2014), who showed that the pig intestinal tissue (mounted in the InTESTine™ system) P_{app} values are more comparable to human P_{app} values compared to Caco-2 P_{app} values.

Oral absorption and bioavailability

Much of this previous review, along with literature to be cited, allows these writers to reach the conclusion that the minipig would be a good candidate animal model to

explore drug absorption and disposition with the reasonable expectation that the data will reflect those processes in humans. Others have expressed the same opinion, which is based on measurable similarities between the two species in most aspects of physiology and biochemistry of many, if not all, body systems. The caveat, of course, is that our current state of knowledge is far from being complete and, as with any model, refinements and adjustments need constantly to be made to achieve better (but not perfect) predictability.

Animal models are typically used to assess the absorption, bioavailability and pharmacokinetic behavior of orally dosed NCEs during drug discovery and early preclinical phases of drug development. Toxicity and safety assessment are determined in parallel studies. Oral dosing experiments are designed to provide an early signal about potential limited absorption and exposure. This, of course, is done in conjunction with an understanding of the physical chemical properties of the drug (e.g., pKa, ClogP, aqueous solubility, *etc.*). While the pig has gained great popularity in recent years, current animal models continue to include the mouse, rat, rabbit, dog and monkey (to some extent). The rat and dog remain the most extensively used, if for no other reasons than the existence of large data bases (and appropriate experimental facilities and experience) and their use in toxicity studies. The dog allows oral dosing of conventional dosage forms used in humans, unlike the rat. We conducted a review of the literature some years ago to obtain an estimate of bioavailability (BA) in the dog, expressed as the fraction of the dose absorbed systemically (F), and we calculated an r^2 value of about 0.24 in a plot of F_{human} vs. F_{dog} (Zhang, Tang and Mayersohn, unpublished). More recently, Musther *et al.* (2014) reported on extensive analyses correlating oral BA in humans and mouse, rat, dog and

non-human primates. The results were disappointing with r^2 values of 0.253, 0.287 and 0.374 for the mouse, rat and dog, respectively. An r^2 of 0.694 was obtained for the non-human primates; perhaps as good a correlation as one might expect to reasonably achieve. Correlation did not improve when considering ionic class (acid, base, neutral, Zwitterion). One would expect that these correlations would improve, perhaps dramatically, if: standard experimental procedures were used in all cases, the same strain of animal was examined, the same laboratory (and technician) conducted the work and identical sensitive and selective analytical methods were applied.

In preparing to write this minireview of minipigs, we did an analysis of the literature to determine the correlation of oral BA in pigs (F_{pig}) with F_{human} , as done for other species by, for example, Musther *et al.* (2014). We collected and evaluated all comparable F data in humans and pigs, recognizing that such a data set would be quite limited (with the hope of it expanding with time as minipig use increases). We were able to obtain 31 pairs of data (Appendix Table A1). The details of this analysis can be found in the Appendix (further analysis will be submitted for publication). These data are shown in Figure 1 (left), which illustrates the line of identity with lines that define the 2-fold and $\frac{1}{2}$ -fold ranges (*i.e.* a total 4-fold range). Overall, it appears that a low, but not unreasonable correlation exists ($r^2=0.408$); in contrast, the highest r^2 found by Musther *et al.* (2014) was for the non-human primate (NHP), 0.694. The data from that publication analyzed in the same manner, are illustrated in Figure 1 (right), offering a side-by-side comparison of the two species. Both animal species appear to underestimate F_{human} . For the pig, 6 of 31 drugs are outside the 4-fold range (20%); whereas, 15 of 41 drugs (37%) are outside that range for the NHP. As a tentative general rule, If the BA in the pig is over 10%, the corresponding

BA in humans will be over about 30%. A similar conclusion for the non-human primates suggests that BA values greater than 10% corresponds to a BA in humans greater than about 20%. Clearly, this is not a rigorous rule, but it deserves testing until additional data are generated. What is missing in this analysis are insights into the BA differences between the two species, what are the causative mechanism(s), especially for those drugs having more than about a 2-fold difference between the two species. It is this mechanistic understanding that will ultimately provide the insight needed to design the appropriate studies and assist in resolving practical issues of poor BA in humans.

We consider here, briefly, those drugs from the above analysis having a greater than 2-fold difference between human and pig. Diclofenac is an exceptional example as it is the only drug in which F_{pig} was much greater than F_{human} (*viz.*, 100% *v.* 42%). This is likely to be explained by a greater hepatic first-pass effect in humans due to the higher CYP2C activity in humans (Oberle *et al.*, 1992; Willis *et al.*, 1979). Midazolam BA in pigs (*ca.*, 5-14%), while similar to that in the rat and dog, is much lower than that in humans (*ca.*, 34%). This appears to be due to the greater systemic (primarily hepatic) clearance which approaches liver blood flow in pigs (Lignet *et al.*, 2016). Cimetidine has a higher metabolic clearance in minipigs, resulting in a higher hepatic and/or intestinal first-pass effect, which may be the cause for lower oral BA in the pig (*ca.*, 33 *vs.* 78%; Lignet *et al.*, 2016). In pigs, finasteride has an oral BA of 40% compared to 80% in humans and, again, this may be explained by greater hepatic/intestinal extraction in the pig (Lundahl *et al.*, 2011). Antipyrine has a low systemic clearance in both pigs and humans and, furthermore, a sex-related difference was noted in both species. While the *in vitro* hepatocyte clearance was low and similar in the two species, the oral BA of about 30%

in both male and female pigs was much lower than in humans (ca., 100%). This discrepancy can be explained by either lower absorption in pigs and/or higher extraction in the GIT. Since antipyrine is a BCS Class I compound, differences in absorption between the species is unexpected. It is possible, as with midazolam, which undergoes GIT extraction (Thummel *et al.*, 1996) that antipyrine is also extracted by the GIT preferentially in the pig. This possibility needs to be explored. The tetracycline derivatives (tetracycline, oxytetracycline and chlortetracycline) have significantly lower BA in both fed and fasted pigs compared to humans. Since tetracycline and oxytetracycline are eliminated primarily by renal excretion and have good solubility at the pH of the GIT fluids, first-pass effects cannot explain the disparity. These compounds are well known to form insoluble complexes with heavy metals present in the gut that decreases absorption, which, if the cation composition of the gut fluids of the pig are different from humans, could explain the lower BA, but this is speculation.

While the above review and analysis provide a reasonable basis to view the minipig as a promising animal model to examine human drug absorption and BA, there is need for harmonization and standardization to the extent possible. Ideally, a single breed of minipig or micropig could be used, possibly the Göttingen strain, because of its past and current widespread utilization (especially in toxicity studies). Their small size is a real advantage to housing and handling as well as requiring less drug, an important consideration in early discovery programs. Protocols should be standardized as to feeding (throughout the day or twice a day), type of food and the choice of male (castrated or non-castrated) or female animals, unless, of course, the study intention is to examine sex-related effects. The age of the animal is a consideration, most likely selected at sexual

maturity, unless younger or aged animals can be shown to reflect maturation or aging effects in humans. Since pigs have the advantage of placement of vascular access ports (e.g., Bailie *et al.*, 1986; Myers *et al.*, 2016) that can remain patent for long periods, the experimenter has the advantage of considering multiple cross-over studies each requiring frequent blood sampling of long duration. It is important that there be robust data analysis and clarity in reporting the study design and results in order to maximize the information provided by the study and to minimize the bias or loss of information. Much of the literature is devoid of these important details. Specifically, there should be examination of drugs with low BA in humans since the current data analysis and interpretation was limited to compounds with BA values greater than 10% in humans. We encourage research in comparing the oral bioavailability for drugs with lower BA in humans (<10%). We also suspect that there is a considerable amount of in-house data that might address this issue and we encourage the industry to publish such data (especially those that appear to be failures in correlating with human results).

***In vitro* and in vivo porcine prediction of *in vivo* human clearance**

There have been generally two schools of thought when attempting to predict human clearance, CL; *in vitro*-based (usually referred to as *in vitro-in vivo* extrapolation, IVIVE) and *in vivo*-based empirical methods (Obach *et al.*, 1999; Houston, 2013; Tang and Mayersohn, 2005a; Rostami-Hodjegan, 2017). Although physiologically-based pharmacokinetic (PBPK) models are generally recognized as a more mechanistically-based methodology in describing and predicting human PK, these models depend upon IVIVE values for estimates of CL. Those estimates are critical to the success of the model

as the clearance parameter depends upon organ extraction ratios and organ blood flows, the driving force behind all PK processes that drugs undergo in the body. In reality, both methodologies have been widely used in practice, since neither method is completely satisfactory (Ring *et al.*, 2011; Hosea, 2009). In addition, the real situation with regard to predicting human PK parameter values is usually more complicated than what is typically portrayed in most publications. For instance, the totality and quality of the data vary with the project stage (*e.g.*, discovery screening data are usually much more limited) and vary also with the nature of the compounds (*e.g.*, current NCEs are more complex and lipophilic, which results in variable *in vitro* and *in vivo* PK behaviors). High plasma protein binding estimates *in vitro* are often associated with quality of measurement issues. *In vitro* metabolic incubation, especially with hepatocytes, is often associated with high variability from batch to batch and technician to technician working on the project and numerous other uncontrolled factors. Many of these complexities, both *in vitro* and *in vivo*, are not reflected in many scientific publications. Therefore, based on the authors' experience with several large pharmaceutical companies and personal communications among active scientists in the field, both *in vitro*- and *in vivo*-based methods are always considered for incorporation into appropriate models for predicting human PK.

IVIVE: Lignet *et al.* (2016) conducted a comprehensive IVIVE study in minipigs (adult male and female Göttingen) with seven reference compounds (antipyrine, atenolol, cimetidine, diazepam, hydrochlorothiazide, midazolam and theophylline) following intravenous and oral dosing. CL values ranged from low to high (near liver blood flow). *In vitro* data were generated on hepatocellularity, metabolic clearance in hepatocytes and blood and plasma protein binding. The estimated *in vitro* intrinsic clearance, CL_{int} , and

CL_{int} from *in vivo* experiments illustrated an overall good correlation between minipigs and humans, with only one significant outlier (cimetidine, 11-fold difference). When incorporating plasma protein binding, *in vitro* binding in incubations and blood/plasma ratio into the IVIVE model, the predictions seemed to get much worse. This has been observed by other investigators, where consideration of plasma protein binding made the predictions worse (e.g., Poulin, 2013). Researchers have been making modifications to existing models and progress continues to be made in the IVIVE arena, as with the introduction of the unbound liver fraction idea (Poulin, 2013; Poulin and Haddad, 2018). However, the IVIVE approach remains associated with uncertainties due to the complexity of the “true” mechanistic models, which may differ, in some aspects, among compounds and the measurement of uncertainties in the *in vitro* assays. Overall, the prediction performance of IVIVE in minipigs is generally similar to what has been observed in humans.

***In vivo*-based methods:** Yoshimatsu *et al.* (2016) conducted PK studies with 14 compounds in three species: mouse, rat and male NIBS minipigs (3 months of age). Single-species allometry of CL with or without correcting for plasma unbound fraction (f_{up}) was used to predict human CL by fixing the allometric exponent at 0.75. The more conventional allometry using three species was also examined with or without correction for brain weight (BrW) or maximal life-span potential (MLP) (Mahmood and Balian, 1996). Overall, the predictions based on either the minipig single-species method or conventional allometry, which included all three species, performed better than other *in vivo* methods. The single-species method performed similarly or better than the three-species method. This is not a surprising observation by virtue of the mathematical nature

of the analysis; the conventional multiple-species allometry method depends on the predictability of the species having the largest weight, in this case the minipig (Tang and Mayersohn, 2005b). Adding more species to the allometric analysis, especially a species having “less predictability” or “error” among the lower body weight species may amplify the “error” of prediction. Correcting for BrW or MLP, the “rule of exponents” (ROE) (Mahmood and Balian, 1996), is equivalent to applying some constants to the predictions, which are not based on any mechanistic foundation (Tang and Mayersohn, 2005c). It should also be noted that Yoshimatsu *et al.* (2016) found an excellent, predictive relationship for unbound apparent volume of distribution in humans from the minipig data (all data within a 4-fold range of values). With few exceptions, the unbound fractions of drug in the plasma were essentially the same when comparing the minipig and human. The intravenous data reported in this study will be used in the following section to evaluate an *in vivo*-based method for predicting human CL.

It should also be noted that there exists a large body weight gap between a typical dog (such as the Beagle, ca. 10 Kg) and a human adult (ca., 70 Kg) in a conventional allometric model. The pig will represent a larger animal species, closer in body weight to humans, which mathematically exerts the largest impact in predicting human parameters in the allometric model (Tang and Mayersohn, 2005b). As discussed in previous sections, pigs resemble humans in many important pharmacokinetic aspects (physiological/metabolic/transport, *etc.*). Thus, pigs as a predictive species with a closer body weight to humans is expected to improve the predictability of human parameters with the allometric model.

Data collection and reanalysis: This section presents the development of a single-species allometric analysis for predicting human CL based on CL measured in minipigs. Literature data for intravenous dosing were collected and evaluated (n=40 drugs; see Appendix Table A2), including the data from Yoshimatsu *et al.* (2016) (n=14), Lignet *et al.* 2016) (n=7) and Mogi *et al.* (2012) (n=5). A simple allometric relationship was employed,

$$\left(\frac{CL}{kg}\right)(HUMAN) = coefficient \cdot \frac{CL}{kg}(PIG)$$

Where the 'coefficient' is optimized by minimizing the absolute average fold-error (AAFE),

$$AAFE = e^{(\sum \ln|\frac{pred}{obs}|/N)}$$

The resulting equation, after optimizing the coefficient, was determined to be,

$$\left(\frac{CL}{kg}\right)(HUMAN) = (0.314) \cdot \frac{CL}{kg}(PIG)$$

Overall, the prediction performance based on the *in vivo* minipig data appears to be acceptable; better than the single-species methods based on rat and dog, and similar to the single-species method based on the monkey, which were developed with the same methodology (n=102; same model and optimization). The overall AAFEs from our analysis of the minipig data were 1.96 vs. 2.35, 2.52 and 1.90 for the rat, dog and monkey, respectively. The single-species data showed the same AAFE as found in the monkey data, but improved values over the rat or dog (Table 1). The coefficient from the pig analysis, 0.314, was lower than that from the dog (similar body weight) 0.410 and the monkey (generally lower body weight) 0.467, indicating that the metabolic activities were generally higher in pigs than those in the dog or monkey. The latter conclusion is

consistent with our observations in the previous section that oral BA was generally lower in pigs, likely due to the relatively greater value of CL in pigs. Results of the allometric analysis are illustrated in Figure 2, which show the line of identity along with the 3- and 1/3-fold ranges.

It is worth noting that the single-species models above, are the other mathematical forms of the allometric models with fixed exponents (*Tang et al.*, 2007). The single-species methods have been extended to the scaling of unbound total CL (CL/f_{up}) by some investigators as well as in practice in the industry. The thinking behind such corrections by f_{up} is based on the hypothesis that plasma protein binding, which does not scale by body weight, may vary across species; thus, excluding such a confounding factor may better reflect the allometric relationship of body weight and organ elimination capacity (a hybrid of organ weight and enzymatic/excretion activity). There have not been robust data and analyses done to evaluate this approach, however. It should also be noted that, for high plasma protein binding drugs (ca., >95%), the measurement errors associated with such binding are high, thus, correcting for such a parameter introduces another substantial random error.

While the results of the above analyses are promising with regard to the use of minipigs for predicting human clearance, the data base currently available is limited and needs to be extended and, as noted above, standardized experimental procedures need to be applied. Of greatest interest and challenge, is a mechanistic understanding of the reasons behind those drugs that are outside (often substantially outside) the 9-fold range of prediction.

Physiologically-based pharmacokinetic (PBPK) models

PBPK models, since they were first conceptually elaborated and applied by Bischoff and Dedrick (1968), have, in recent years, become increasingly important tools for drug development by the pharmaceutical industry in understanding and predicting pharmacokinetic behavior of NCEs (e.g., Rostami-Hodjegan and Tucker, 2007; Rowland *et al.*, 2011; Zhao *et al.*, 2011). PBPK models integrate experimental pharmacokinetic-relevant data with current knowledge of physiology, assuming certain mechanistic models and attempt to quantitatively describe and predict the pharmacokinetic behavior of drugs. Such a model is essentially an expression of all of the information and methodologies discussed in the previous sections of this minireview (i.e., from basic physiology, *in vitro* metabolic and transporter processes, *in vivo* pharmacokinetic data, etc.). This section will focus on a review of the current application and limitations of these of PBPK in pigs and propose future work. All of the effort invested in developing a PBPK model is directed towards the prediction of pharmacokinetic behavior of drugs, especially NCEs, in humans.

Publications dealing with PBPK models in pigs have been limited and they are directed to: 1. data compilation and model development; 2. evaluation of formulations (typically oral); 3. predicting human pharmacokinetics.

1. Data compilation and model development: While there have been summaries of various physiological values in pigs (e.g., Hannon *et al.*, 1990; Upton, 2008), Suenderhauf and Parrott (2013) took the initiative in reviewing and compiling basic physiological, biochemical and pharmacokinetic data in Göttingen minipigs and, from that, developed a PBPK model used to evaluate two drugs, moxifloxacin and griseofulvin (both were dosed intravenously and orally). This is an important reference, which offers the basis for development of any PBPK model in Göttingen minipigs. Suenderhauf *et al.* (2014) further

tested a PBPK model with a frequently used reference compound, acetaminophen (paracetamol), to evaluate gastric emptying in Göttingen minipigs. The drug was given orally as a solution, capsule and tablet forms and the *in vivo* GE rates were estimated using a deconvolution method. Consistent with previous discussion, the GE was slower than found in humans, possibly due to the presence of food in the stomach. In a fed state the GE was prolonged and more variable, as has been noted in humans. Sjögren *et al.* (2012) used another test drug, repaglinide, to investigate the interplay of metabolism and transport and its effect on the drug's pharmacokinetics based on *in vitro* and *in vivo* data obtained from pigs (Yorkshire and Swedish Landrace). The drug is eliminated primarily by CYP3A4 and 2C8 metabolism and glucuronidation. It is also a substrate for organic anion-transporting polypeptide (OATP) 1B1. Drug-drug interactions have been reported involving both uptake transport and metabolic inhibition in humans, where cyclosporine or gemfibrozil could markedly increase the plasma concentrations of repaglinide. Based on the *in vitro* metabolic data from microsomes and hepatocytes and transport data, the investigators developed a PBPK model, which was able to quantitatively predict the *in vivo* pharmacokinetics.

There are several considerations, first, it is important to note that the compilation of the data by Suenderhauf and Parrott (2013) establishes the need for a unified pig model, since differences are likely to exist, which will impact the results, such as: breed, food and feeding pattern, age and sexual maturation, sex, *etc.* Body weight, tissue composition, growth curve, metabolic enzyme activities are also likely to vary among breeds. Several of these differences have been noted in previous sections. Importantly,

to the extent possible, these variables need to be controlled for and standards established for experimental designs.

A second important note is with respect to the unique features of gastric emptying in the pig compared to humans. This process may control rate and perhaps extent of oral absorption for some classes of drugs (e.g., Class I of the BCS and poorly soluble weak basic drugs). We have discussed this issue previously.

The third note of caution is with regard to all PBPK models being developed for any animal species, and that is to clearly understand the assumptions that are going into the model. Many physiological and biochemical parameters were assumed in model development for minipigs; some were made between species, some were made between the breeds of pigs. A sensitivity analysis around these assumptions should be conducted in order to evaluate the impact of the assumptions on the outcomes of the endpoints of greatest interest. This is generally true of all PBPK models, however, it may be even more important and mandatory for PBPK models developed in pigs, since data and experience are much more limited than, for example, rats and dogs. It is useful to keep in mind that PBPK model development and its applications require a considerable amount of “rich” experimental data (*in vitro* and *in vivo*), derived from extensive labor-intensive efforts, the need for rigorous quantitative methods of analysis, an understanding of multiple scientific disciplines and clarity and effectiveness in communicating PBPK information (especially assumptions made) for decision-making. Such requirements limit the wide application across all drug discovery and development stages. With regard to the development of PBPK models in the pig, consideration should be given to the relative value(s) obtained from the required scientific/time/cost effort. In that regard, the following sections examine

the potential value that investigators may want to offer by applying the PBPK approach in pigs; formulation assessment and human pharmacokinetic predictions.

2. Formulation assessment: Dogs are typically used for preclinical evaluation of formulations, especially for the prototype formulations intended for humans. However, for many reasons, some of which have been discussed above, the dog is not the most appropriate non-rodent species for many oral dosing scenarios; mostly based on substantial differences in the GIT compared to humans. For example, the dog has a much shorter small intestinal transit time compared with humans (which may be inappropriate for evaluating extended release products) and they have a higher and more variable intestinal pH than in humans (Dressman, 1986). Exploration of the pig model as an alternative may be necessary. Kesisoglou *et al.* (2013) used the Yucatan minipig to develop a level C *in vitro-in vivo* correlation for a BCS class III extended release matrix tablet. The food-effect study, however, was shown to be “challenging”. Kesisoglou *et al.* (2016) developed a PBPK model for the dog to describe absorption in the large intestine for a BCS class I drug dosed *via* ileal and colonic ports to evaluate region-dependent absorption. A minipig absorption PBPK model was also developed by using the default minipig ACAT model in “Gastro-Plus” and assuming regional absorption differences to be the same as in the dog. (The grossly different GIT anatomy between the two species makes this a questionable assumption.) Two extended release formulations were tested in minipigs and the pharmacokinetic results were reasonably well predicted by the PBPK model along with the *in vitro* dissolution data. This work generally showed the utility of the PBPK approach, especially that the PBPK-predicted extended release pharmacokinetic

profile predicted the observed data, reflecting a correlation between the *in vitro* profile and the regional absorption characteristics.

A few observations are in order. A full description of the proposed PBPK model is essential. While it might be clear to those investigators using specific software packages, for example (in this case “Gastro-Plus”), it is difficult for other investigators to follow and understand the work, nor is the methodology transferable if other tools are used to analyze the data. For example, the study used castrated male minipigs of about 50 kg. Questions that may arise: are there specific GIT parameters for the 50 kg Yucatan minipig?; what are the values for gastric emptying, since GE may be different from other species as shown in many publications?; what are the values for GI fluids? PBPK modeling is associated with many assumptions and the evaluation of those assumptions is important. Missing or incomplete information about those assumptions will inevitably create problems of reproduction. The authors encourage that all modeling work, especially PBPK models, present the fullest and clearest set of assumptions used in creating the model (perhaps in some supplementary format).

Research allowing comparison with human data is encouraged. The only way to further develop and confirm the usefulness of a model, is to continue to test it. While this may provide an initial burden for the industry, which will benefit the most, establishing a useful animal model would go a long way in developing predictive models for humans. The animal model must be able to distinguish, for example, among dosage forms of the same drug. Those *in vivo* data in conjunction with *in vitro* data (especially for extended release forms) would be expected to offer a useful *a priori* insight into the human profile.

Having such confidence, will only evolve from establishing human and pig comparability over a wide spectrum of drugs/dosage forms.

3. Human pharmacokinetic predictions: Shida and Yamazaki (2016) constructed a series of simplified PBPK models in monkey, dog and pig. The purpose of their modeling work was to predict human pharmacokinetics. The approach was to first construct PBPK models in animals. They then utilized a “scale-up” strategy, which predicts human pharmacokinetic parameters (such as absorption rate constant, central volume of distribution, intrinsic clearance, *etc.*) based on animal values estimated from the model and *in vitro* metabolic data. The test compounds were: caffeine, S-warfarin, omeprazole, metoprolol and midazolam, whose corresponding metabolic CYP isoforms are, 1A2, 2C9, 2C19, 2D6 and 3A4, respectively. The investigators concluded that the PBPK-scaled models predicted the observed pharmacokinetics in humans. It should be noted that this approach is similar to simplified conventional compartmental (*i.e.*, lumped) pharmacokinetic models. The most important human parameters (hepatic clearance, volume of distribution and absorption) were scaled or estimated with common approaches. For example, fixed-exponent allometry was used to scale clearance in rodents to humans; IVIVE was used to estimate *in vivo* clearance. The development of such simplified models may lend certain credibility to using a similar structured model for predicting human pharmacokinetics, however, the extent of any added value from such models may be limited, because the prediction of key pharmacokinetic parameters (clearance, volumes and absorption) is still the fundamental challenge. Then, the key questions that need to be asked are still the same in predicting human pharmacokinetic values: allometry, IVIVE or “scale-up” strategy (a hybrid of allometry and IVIVE in

animals). Whether pigs could serve as an alternative or as a more predictive model of human pharmacokinetics, will require a great deal more data with systematic and robust analyses, as noted previously.

To conclude this section, some considerations for the future. Pig breeds need to be unified and standardized for PBPK development, as for any other purpose. This goal may require some coordinated effort from academia, industry and government regulatory agencies. Gastric emptying seems to be a major unique feature associated with pigs that may offer an obstacle in establishing absorption/bioavailability models and in examination of fed vs. fasted states. Again, the best approach would seem to select one breed (e.g., Göttingen) for further examination or, in the alternative, determination of that breed which is least susceptible to GE limitations or food effects. Studies of different drugs/dosage forms is necessary with comparison with human data. A major value of a porcine model may well be as a screen for oral dosage forms and its relationship to human absorption, limitations discussed notwithstanding. Predicting human pharmacokinetic parameter values from a porcine-based PBPK model appears to have potential; however, the prediction of key driving parameters (for example, systemic CL) remains the major challenge.

Evaluation of formulations

Development and assessment of drug dosage forms are essential functions of any research and development division and, for which, having a predictive animal model would be a *desiderata*. We have noted in several sections, above, numerous issues associated with the pig that may compromise or make challenging the use of a porcine

model for assessment of (especially) oral dosage forms; advantages are also noted. Disadvantages also exist for the dog in this regard but which is the most often relied upon model. We have also cited several publications that have examined the drug absorption process in the minipig (*e.g.*, Henze *et al.*, 2018; Suenderhauf *et al.*, 2014). In this section we discuss several other specific examples where drug dosage forms have been assessed in the pig and for which there are relevant human data. Many other studies have been published, but for which there are no comparative human data, making it difficult or impossible to assess the suitability of the animal model.

Christiansen *et al.* (2015) examined the effect of food on the oral absorption of pravastatin and atazanavir, two low aqueous solubility drugs in Göttingen minipigs. They used a protocol similar to one used in dogs (Lentz *et al.*, 2007). GE was followed with co-administration of oral acetaminophen (as a marker of GE). As noted by others, GE times were prolonged in the pigs (2.3-8.4 hr); however, there was no food-effect seen. Pravastatin and atazanavir have shown positive and negative food-effects, respectively, in humans. The results of this study challenge the idea of using the pig as an animal model for studying food effects in humans. The investigators conducted a study to examine the impact of a pharmacological agent that promotes GE, metoclopramide, in order to “normalize” GE. That agent was found to have no effect on GE in a fed or fasted study, again, questioning the pig as an appropriate animal model for examining food effects.

Drug absorption from modified (*i.e.*, controlled or sustained) release dosage forms has been examined in numerous studies. Kulkarni *et al.* (2012) compared the absorption of immediate and modified release in immature farm pigs (*ca.*, 3.5-4 month; 21-27 kg)

and dogs (apparently under fasting conditions). The results suggested that the pig may be more suitable an animal model on the basis of smaller variance in AUCs and a higher BA (ca., 80%, similar to humans). The lower BA value in the dog may reflect the shorter GI transit times, not allowing sufficient time for absorption. Based on the similar plasma concentration-time profiles for the immediate and modified release forms in the pig, there was no suggestion of a delay in GE. Genissel *et al.* (2004) examined the absorption of trimetazidine from an oral solution, immediate release and sustained release dosage forms in pigs (24.2-31.8 kg) and dogs. The IV data indicated greater clearance in the pig with a corresponding greater first-pass effect associated with the oral forms. The plasma concentration-time data in pigs suggested no delay in absorption with mean absorption times being similar in the two species. Either species appeared to be an adequate model for the evaluation of the modified release form. Ikegami *et al.* (2006) studied controlled release theophylline absorption in dogs, monkeys and pigs (Göttingen; 10-12 kg). Even after 20 hours of fasting, delay in absorption in pigs was seen. The relative BA was 33% and 47 % in the dog and pig, respectively, compared to 80% in the monkey. There was no relationship between *in vitro* and *in vivo* release in dogs and pigs and the authors concluded that the monkey is the better animal model. One reason for the lower BA in the pig may be incomplete estimation of AUC, whose value may be affected by GE. The low BA in the dog may be due to the short GI transit time, as noted before. Here as elsewhere, a more complete IVIVC and comparison with human data would be ideal.

Ramsay-Olocco *et al.* (2004) used Yucatan micropigs (25.3-51 kg) to examine the effect of vitamin E TPGS on intestinal permeability for P-gp efflux of a substrate with high solubility and low permeability. Although there was large variability with TPGS, there was

a suggestion of improved BA with TPGS (25% to 44%). In humans, no improvement was observed with TPGS. It should be noted, however, that the human dose was 5 mg, while that in pigs was 50 mg. Considering the approximately 3-fold difference in body weight, the actual dose/kg difference may be up to 30-fold. Thus, the actual amount of TPGS in humans was substantially lower per intestinal volume or area, which could lead to minimal impact of TPGS in P-gp inhibition. This point emphasizes the importance of quantitative analysis and design of studies (*e.g.*, effective inhibitory concentrations in *in vivo* luminal contents).

The above brief presentation makes clear that the pig may not be an “ideal” (if such a thing exists) animal model for examination of dosage form performance, at least with regard to food-effect studies; it may prove to be at least as good as other animal models. The pig is likely to be useful as a pre-clinical screen for quantifying dosage form differences and serve to reflect the human condition. At the current time there is too little rigorous information, especially in comparison with human data, to reach an unequivocal conclusion; time will tell.

Dermal absorption

Dermally applied dosage forms for the transdermal delivery of drugs has become an increasingly important route of administration, having significant advantages in terms of convenience to the patient, slow and prolonged absorption profile and avoidance of GIT first-pass effects (Paudel *et al.*, 2010). Predicting human exposure, therefore, becomes an important task, as it is for other routes of administration. Excised human cadaver skin is considered the “gold” standard for predictive purposes (*e.g.*, Franz *et al.*,

2009). However, there are significant limitations to the *in vitro* use of human cadaver skin including the high cost and availability (e.g., there is no human skin bank in China), experimental variations due to the limited supply of samples and the potential differences between the *in vitro* skin testing system and the *in vivo* performance of skin. *In vitro* models are only quantitatively useful for predictive purposes when a correlation exists between the *in vitro* and *in vivo* systems; reflecting the need for an IVIVC. Potential causes for a lack of correlation include blood flow (vs. sink conditions), local pH and temperature and metabolism (due to cryopreservation, etc.) (Pershing *et al.*, 1989; Auclair *et al.*, 1991; Clarys *et al.*, 1998; Manevski *et al.*, 2015). The method of skin preparation can be critical to the experimental results with regard to lag times and permeability measures. For example, the lack of a blood flow causes the lower portions of the dermis to act as a rate-limiting step for transport, a barrier that would not exist *in vivo* (Takeuchi *et al.*, 2012). There are numerous studies showing that human skin contains most of the enzymes found in other major elimination organs (e.g., CYPs, phase II enzymes such as GST, UGT, NAT, etc. and others including, FMO, cyclooxygenases, ADH and ALDH, esterases/amidases, etc.) (e.g., Oesch *et al.*, 2007). Information about skin metabolism in pigs is limited; however, substantial metabolism may exist for certain drugs, but this will depend upon the processing and preservation conditions of the skin. Yucatan micropigs resemble humans with regard to esterases and albumin seemed to affect the preservation of its activity (Rangarajan and Zatz, 2001).

While rats are readily available for such studies, significant differences have been found between rat and human skin; rodent stratum corneum is thinner, which may lead to the observed higher permeability noted in rodents. Pig skin is much more similar to

human skin with regard to thickness of the stratum corneum, lipid components, *etc.* (Priborsky *et al.*, 1990; Stricker-Krongrad *et al.*, 2017). As we noted above, “The minipig is the species of choice to investigate dermal absorption in preclinical drug development.” (Preube and Skaanild (2012)). The intent of this brief review of dermal absorption is to focus on several publications that have evaluated transdermal drug absorption comparing *in vitro* and *in vivo* data in the pig (Yamamoto *et al.*, 2017; Yoshimatsua *et al.*, 2017). We also provide in-house data generated at Guangzhou Dazhou Biomedicines Ltd. (unpublished) to illustrate the development of an IVIVC in order to demonstrate the utility of this approach.

Transdermal IVIVC in pigs: Yamamoto *et al.* (2017) studied several drugs (nicotine, rivastigmine diclofenac and lidocaine) *in vivo* in 4 minipigs (5 months; 10.0-14.4 kg; breed not reported) by application of the dermal product to the back of the pig. Cryopreserved excised Göttingen minipig skin (male; 5 months; 9.3 kg), was cut from the back of the minipig and dermatomed to a thickness of 400-600 μm . Cryopreserved excised human skin was obtained from female Caucasian human subjects (during abdominal plastic surgery). The human and pig skin permeabilities of the test drugs generally showed similar time-course profiles, with the pig having about a 2-fold higher permeability. Using the *in vitro* pig permeability data and convoluting with the human systemic drug disposition data the human pharmacokinetics following dermal application were reasonably well predicted. The observed AUC and C_{max} values were about within a 2-fold range of predictions. T_{max} varied, though, suggesting that the delayed appearance of the drugs in the circulation may not be adequately captured by the *in vitro* permeability studies. This thorough study, with some limitations, reported the following information: *in*

vitro permeability in pig skin; *in vitro* permeability in human skin; *in vivo* pharmacokinetics following dermal application in pigs; *in vivo* pharmacokinetics following dermal application in humans; *in vivo* systemic pharmacokinetics in humans (literature data). What is missing is the systemic pharmacokinetic profile in pigs and an analysis of the *in vitro* and *in vivo* relationship in pigs. It was not clear how the BA was obtained without systemic pharmacokinetics in the pigs, although an estimate might have been obtained from analysis of the residual drug in the dermally applied formulation. The more complete study design would include an IV arm in the same pigs, together with the thorough data analysis as noted:

- IV pharmacokinetics in the pig
- *in vivo* estimation of absorption in pigs (e.g, by deconvolution)
- evaluation of correlations between *in vitro* and *in vivo* data in both pigs and humans
- quantify the *in vitro* and *in vivo* correlation in pigs and predict human *in vivo* transdermal absorption with and without considering the correlation in pigs.

The *in vitro* and *in vivo* correlation established in pigs will lend more confidence in predicting human pharmacokinetics. If the human pharmacokinetic predictions turn out to be substantially different from those based on the *in vitro* human permeability, there is a reference in pigs to evaluate whether the *in vitro* system is appropriate for prediction purposes. Completeness in the IVIVC data and methodology for both pig and human is important. Ultimately, if experimental protocols can be standardized (such as pig breed, dermatome methodology, storage of skin, Franz cell setup, *etc.*) and generally agreed

upon, and the *in vitro* data are found to have adequate correlation to *in vivo* results, then human skin studies need not be done; that is, prediction of human pharmacokinetics directly based on *in vitro* pig permeability, as demonstrated by Yamamoto *et al.* (2017).

Yoshimatsu *et al.*, (2017) conducted *in vitro* and *in vivo* studies on six drugs (ketoprofen, flurbiprofen, diclofenac, buprenorphine, fentanyl and lidocaine) in mice, rats, minipigs and humans (diclofenac and lidocaine data from the Yamamoto *et al.* study (2017)). The study protocols were basically the same as in Yamamoto *et al.* (2017). The results indicated considerably lower *in vitro* and *in vivo* permeability in pigs compared to the other species, including humans. For example, the ratios of the fractions permeated *in vitro* at 24 hours between humans and pigs for the six drugs varied from 4.58 to 34.5; whereas, the differences observed in the Yamamoto *et al.* study (2017) were all within about 2-fold. It is difficult to explain the much lower permeability in pigs noted in this study, especially since 2 of the drugs were the same in both studies.

In-house experience with pig transdermal models: In our experience, *in vitro* pig and human skin generally showed similar permeabilities, as has been reported by others (e.g., Rohatagi *et al.*, (1997)). Skin was dermatomed to a thickness of 400-600 μm from the back of Göttingen minipigs. The Franz cell was used to determine *in vitro* permeability. An example design of IVIV studies and analysis is shown in Figure 3. Three minipigs were used in a cross-over design and three dose groups (IV, patch formulations A and B). This design generates, in the same animal, systemic and absorption pharmacokinetics, allowing estimation of *in vivo* absorption for the individual, controlling the inter-individual differences in systemic disposition and increasing the power of the analysis. The two patch formulations were made to give different release rates and thus to provide different

permeabilities, allowing the development of an IVIVC for one formulation and external validation with data from the other formulation. In addition, a minipig skin bank was established in-house. As long as the two formulations were tested with the same pig skin (Pig N in Figure 3), the effect of any differences in absorption between the *in vitro* (Pig 1) and *in vivo* (Pig N) results that are due to differences in the skin behavior between the two pigs, may be cancelled in terms of predicting the *in vivo* PK for Formulation B. Note, the above cross-over design with N=3 and the IVIVC analysis method is not intended for meeting the criteria for IVIVC *per* FDA's guidance (1997) on the development, evaluation, and applications of IVIVC for extended-release (ER) oral dosage forms. Rather, the cost-efficient IVIVC study design and analysis as illustrated (and the similarity in *in vitro* permeability between the two species) will achieve the following: provide confidence in predicting human transdermal PK based on *in vitro* permeability with human skin under the same experimental conditions as in minipigs; facilitate an optimal study design in humans (for example, by examining the time-course and PK profile in minipigs, which may demonstrate the delay in PK exposure, skin retention of drugs, *etc.*); and allow a reasonable definition of the product profile at an early stage of drug development.

As we have noted in previous sections, there needs to be standardization of methods and experimental protocols. We cannot explain some of the dramatic disparities noted in the literature; however, effort needs to be expended to attend to and resolve those differences. Studies need to be well designed and data analyses need to be robust and complete, as we tried to exemplify in the above in-house example, in order to realize the full potential value of an IVIVC.

SUMMARY AND CONCLUSIONS

The swine has played an important role in biomedical research and current literature suggests a greater awareness of that role, which is expected to increase markedly with time. We have attempted to review here those biological aspects of the pig, and its similarities to humans, that make it an attractive animal model in drug discovery and development. Needless to say, there are always limitations to any animal model used to make predictions in humans; as noted, these are models of, not duplicates of humans. What does the future hold? We fully expect that use of mini-pigs will gain greater momentum in the immediate future. As we have noted, it is important that standardization be applied across studies (and organizations) in order to optimize experimental results and minimize variability. Among those considerations are: selection of the mini-pig breed, type of diet and frequency of feeding, *etc.* An area of research that does not seem to have been explored is pharmacodynamics (PD). The mini-pig can be instrumented to provide PD measurements and to offer PK/PD model development. We look forward to those developments. The authors indeed believe that there is a “pig in the poke”.

Acknowledgements

We gratefully acknowledge the time and effort of Ms. Jennifer Martin, University of Arizona Health Sciences Library (librarian par excellence) in conducting a maxi-literature search for this mini-review. We would like to thank Da Zhang, Ph.D., for sharing the oral bioavailability data in dogs and humans; Hock Tan, Ph.D. and Wenfei Liang, for providing the GDB in-house experience on transdermal *in vitro* and *in vivo* studies in humans and pigs.

Authorship Contributions:

Participated in research design: Tang and Mayersohn.

Performed data analysis: Tang and Mayersohn

Contributed to the writing of the manuscript: Tang and Mayersohn

References

- Achour B, Barber J and Rostami-Hodjegan A (2011) Cytochrome P450 pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectroscopy. *Drug Metab Dispos* **39**: 2130-2134.
- Anzenbacher P, Soucek P, Anzenbacherova E, Gut I, Hruby K, Svoboda Z and Kvetina J (1998) Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human samples. *Drug Metab Dispos* **26**: 56-59.
- Aoyagi N, Ogata H, Kaniwa N, Uchiyama M, Yasuda Y and Tanioka Y (1992) Gastric emptying of tablets and granules in human, dogs, pigs, and stomach-emptying-controlled rabbits. *J Pharm Sci* **81**: 1170-1174.
- Argenzio RA and Monteiro-Riviere NA (2001) Excretory system, in *Biology of the Domestic Pig* (Pond WG and Mersmann HJ, eds.), pp. 589-593, Cornell University Press, Ithaca, NY.
- Auclair F, Besnard M, Dupont C, Wepierre J. (1991) Importance of blood flow to the local distribution of drugs after percutaneous absorption in the bipedicated dorsal flap of the hairless rat. *Skin Pharmacol*. **4**:1–8)
- Bailie MB, Wixson SK and Landi MS (1986) Vascular-access-port implantation for serial blood sampling in conscious swine. *Lab Anim Sci* **36**: 431-433.
- Bischoff KB and Dedrick RB (1968) Thiopental Pharmacokinetics. *J Pharm Sci* **57**: 1346-1351.
- Bode G, Clausen P, Gervais F, Loegsted J, Luft J, Nogues V, Sims J (2010) The utility of the minipig as an animal model in regulatory toxicology. *J Pharmacol Toxicol*

Meth 62: 196-220.

Bogaards JJP, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren J and Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. *Xenobiotica* **30**: 1131-1152.

Bollen PJA, Hansen AK and Olsen Astrup AK (2010) *The Laboratory Swine*, 2nd ed. CRC Press, Boca Raton, FL.

Bon C, Toutain PL, Concordet C, Gehring R, Martin-Jimeniz T, Smith J, Pelligand L, Martinez M, Whitem T, Riviere JE and Mochel JP (2017) Mathematical modeling and simulation in animal health. Part III. Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics (2017). *J Vet Pharmacol Therap* **41**: 171-183.

Box GEP (1976) Science and statistics. *J Amer Stat Assn* 71: 791-799.

Box GEP (1979) Robustness in the strategy of scientific model building, in *Robustness in Statistics* (Launer RL and Wilkinson GN, eds.) pp. 201-236. Academic Press, New York, NY

Bustad LK, McClellan RO and Burns MP, eds. (1966) *Swine in Biomedical Research*. Frayn and McClellan, Seattle, WA.

Casteel SW, Brown LD, Lattimer J and Dunsmore M (1998) Fasting and feeding effects on gastric emptying time in juvenile swine. *Contemp Top Lab Anim Sci* **37**: 106-108.

Christiansen ML, Mullertz A, Garmer M, Kristensen J, Jacobsen J, Abrahamsson B and Holm R (2015) Evaluation of the use of Göttingen minipigs to predict food effects

- on the oral absorption of drugs in humans. *J Pharm Sci* **104**: 135-143.
- Clarys P, Alewaeters K, Jadoul A, Barel A, Manadas RO, Pr  at V. (1998) In vitro percutaneous penetration through hairless rat skin: influence of temperature, vehicle and penetration enhancers. *Eur J Pharm Biopharm.* **46**:279–83.)
- Conn PM (ed.) (2008) *Sourcebook of Models for Biomedical Research*, Humana Press, Totowa, NJ.
- Crouch RD, Hutzler JM and Daniels JS (2018) A novel *in vitro* allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry. *Xenobiotica* **48**: 219-231.
- Davis, SS, Illum L and Hinchcliffe M (2001) Gastrointestinal transit of dosage forms in the pig. *J Pharm Pharmacol* **53**: 33-39.
- DeSesso JM and Williams AL (2008) Contrasting the gastrointestinal tracts of mammals: factors that influence absorption. *Ann Rpts Med Chem* **43**: 353-371.
- Diaz GJ and Squires EJ (2000). Role of aldehyde oxidase in the hepatic *in vitro* metabolism of 3-methylindole in pigs. *J Agricul Food Chem*, **48**: 833–837.
- Dressman JB (1986) Comparison of canine and human gastrointestinal physiology. *Pharm Res* **3**: 123-131.
- Drougas JG, Barnard SE, Wright JK, Sika M, Lopez RR, Stoke KA, Williams PE and Pinson CW (1996) A model for the extended studies of hepatic hemodynamics and metabolism in swine. *Lab Anim Sci* **46**: 648-655.
- Doyle RE, Garb S, Davis LE, Meyer DK and Clayton FW (1968) Domesticated farm animals in medical research. *Ann NY Acad Sci* **147**: 129-204.

- Earl FL, Tegeris AS, Whitmore GE, Morison R and Fitzhugh OG (1964) The use of swine in drug toxicity studies. *Ann NY Acad Sci* **111**: 671-688.
- Franz T, Lehman P and Raney S. (2009) Use Excised Human Skin to Assess the Bioequivalence of Topical Products. *Skin Pharmacol Physiol* **22**:276–286
- Ganderup N-C (2016) Use of swine in biomedical research, in *Swine in the Laboratory*, 3rd ed. (Swindle MM and Smith AC, eds.) p.523. CRC Press, Boca Raton, FL.
- Garattini E and Terao M (2013) Aldehyde oxidase and its importance in novel drug discovery: present and future challenges. *Expert Opin Drug Discov* **8**: 641-654.
- Genissel P, Chodjania Y, Demolis JL, Ragueneau I and Jaillon P (2004) Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. *Eur J Drug Metab Pharmacokin* **29**: 61-68.
- Ghosheh O and Hawes EM (2002) Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. *Drug Metab Dispos* **30**: 1478-1483.
- Gootman PM (2001) Cardiovascular, in *Biology of the Domestic Pig* (Pond WG and Mersmann HJ, eds.), pp 533-559, Cornell University Press, Ithaca, NY
- Hannon JP, Bossone CA and Wade CE (1990) Normal physiological values for conscious pigs used in biomedical research. *Lab Animal Sci* **40**: 293-298.
- Helke KL and Swindle MM (2013) Animal models of toxicology testing: the role of pigs. *Expert Opin Drug Metab Toxicol* **9**: 127-139.
- Henze LJ, Griffin BT, Christiansen M, Bundgaard C, Langguth P and Holm R (2018) Exploring gastric emptying rate in minipigs: effect of food type and pre-dosing of

- metoclopramide. *Eur J Pharm Sci* **118**: 183-190.
- Hesselager MO, Codrea MC, Sun Z, Deutsch EW, Bennike TB, Stensballe A, Bundgaard L, Moritz RL and Bendixen E (2016) The Pig PeptideAtlas: a resource for systems biology in animal production and biomedicine. *Proteomics* **16**: 634-644.
- Higashi E, Ando A, Iwano S, Murayama N, Yamazaki H and Miyamoto Y (2014) Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. *Biopharm Drug Dispos* **35**: 313-320.
- Hossain M, Abramowitz W, Watrous BJ, Szpunar GJ and Ayres JW (1990) Gastrointestinal transit of nondisintegrating, nonerodable oral dosage forms in pigs. *Pharm Res* **7**: 1163-1166.
- Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H *et al.* (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. *J Clin Pharmacol* **49**: 513-533.
- Houston JB (2013) Prediction of human pharmacokinetics in 2013 and beyond. *Drug Metab Dispos* **41**:1973-4.
- Ikegami K, Tagawa K, Osawa T. (2006) Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs. *J Pharm Sci.* **95**:1888-95.
- Jewell J, Prusakiewicz JJ, Ackermann C, Payne NA, Fate G, Voorman R and Williams FM (2007) Hydrolysis of a series of parabens by skin microsomes and cytosol from human and minipigs and in whole skin in short-term culture. *Toxicol Appl Pharmacol* **225**: 221-228.

- Jones R, Marschmann M, Keller M, Qiu, NH, Fowler S, Singer T *et al.* (2016) Shedding light on minipig drug metabolism-elevated amide hydrolysis *in vitro*. *Xenobiotica* **46**: 483-494.
- Kabanda L, Lefebvre RA, Van Bree HJ and Remon JP (1994) *In vitro* and *in vivo* evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil. *Pharm Res* **11**: 1663-1668.
- Kararli TT (1995) Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. *Biopharm Drug Dispos* **16**: 351-380.
- Kesisoglou F, Xie IH, Manser K, Wu Y, Hardy I and Fitzpatrick S (2013) Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III drug development candidate. *J Pharm Sci* **103**: 636-642.
- Kesisoglou F, Balakrishnan A, Manser K. (2016). Utility of PBPK absorption modeling to guide modified release formulation development of Gaboxadol, a highly soluble compound with region-dependent absorption. *J Pharm Sci*, **105**: 722-728.
- Kulkarni R, Yumibe N, Wang Z, Zhang X, Tang CC, Ruterbories K, Cox A, McCain R and Knipp G (2012) Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. *J Pharm Sci* **101**: 4327-4336.
- Lentz KA, Quitko M, Morgan DG, Grace JE Jr., Gleason C and Marathe PH (2007) Development and validation of a preclinical food effect model. *J Pharm Sci* **96**: 459-472.

- Loureiro, A.I., Fernandes-Lopes, C., Bonifacio, M.J., Wright, L.C., and Soares-da-Silva, P. (2013). N-acetylation of etamicastat, a reversible dopamine- β -hydroxylase inhibitor. *Drug Metabolism and Disposition*. **41**:2081-2086.
- Lignet F, Sherbetjian E, Kratochwil N, Jones R, Suenderhauf C, Ottender MB, Singer T and Parrott N (2016) Characterization of pharmacokinetics in the Göttingen minipig with reference human drugs: an in vitro and in vivo approach. *Pharm Res* **33**: 2565-2579.
- Ma H-Y, Yang J-D, Hou J, Zou L-W, Jin Q, *et al.* (2017) Comparative metabolism of DDAO benzoate in liver microsomes from various species. *Toxicol In Vitro* **44**: 280-286.
- Ma H-Y, Yang J-D, Hou J, Zou L-W, Jin Q, *et al.* (2017) Comparative metabolism of DDAO benzoate in liver microsomes from various species. *Toxicol In Vitro* **44**: 280-286.
- Mahmood I, Balian JD. (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. *Xenobiotica*. **26**:887-95
- Manevski N, Swart P, Balavenkatraman KK, Bertschi B, Camenisch G, Kretz O, Schiller H, Walles M, Ling B, Wettstein R, Schaefer DJ, Itin P, Ashton-Chess J, Pognan F, Wolf A, Litherland K. (2015) Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation. *Drug Metab Dispos*. **43**:126-39
- Mayersohn M (2009) Principles of drug absorption, in *Modern Pharmaceutics volume 1: Basic Principles and Systems*, 5th ed. (Florence AT and Siepmann J, eds.), Informa Healthcare USA, Inc., pp 23-80, New York, NY.
- McAnulty, Dayan AD, Ganderup N-C and Hastings KL, eds. (2012) *The Minipig in Biomedical Research*. CRC Press, Boca Raton, FL.

- McCrackin MA and Swindle MM (2016) Gastrointestinal procedures in *Swine in the Laboratory*, 3rd ed. (Swindle MM and Smith AC, eds.), pp. 105-110, CRC Press, Boca Raton, FL.
- McKirnan MD, Gray CG and White FC (1991) Effects of feeding on muscle blood flow during prolonged exercise in miniature swine. *J Appl Physiol* **70**: 1097-1104.
- Meng-Lund E, Jacobsen J, Mullertz A, Jorgensen EB and Holm R (2016) Buccal absorption of diazepam is improved when administered in bioadhesive tablets- An *in vivo* study in conscious Göttingen mini-pigs. *Int J Pharmaceut* **515**: 125-131.
- Mogi M, Toda A, Iwasaki K, Kusumoto S, Takehara H, Shimizu M *et al.* (2012) Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to microminipigs. *J Toxicol Sci* **37**: 1157-1164.
- Monshouwer M, van't Klooster GAE, Nijmeijer SM, Witkamp RF and van Miert ASJPAM (1998) Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. *Toxicol In Vitro* **12**: 715-723.
- Mouley S and Paine MF (2003) P-glycoprotein increases from proximal to distal regions of human small intestine. *Pharm Res* **20**: 1595-1599.
- Musther H, Olivares-Morales A, Hatley OJD, Liu B and Rostami-Hodjegan AR (2014) Animal versus human oral drug bioavailability: do they correlate? *Eur J Pharm Sci* **57**: 280-291.
- Myers DD Jr, Diaz JA, Conte ML and Swindle MM (2016) Cardiothoracic and vascular surgery/chronic intravascular catheterization, in *Swine in the Laboratory*, 3rd ed. (Swindle MM and Smith AC), pp 236-246, CRC Press, Boca Raton, FL

- Nielsen P and Dalgaard L (1978). A sulphate metabolite of trimethoprim in goats and pigs. *Xenobiotica* **8**: 657–664.
- Noer RJ (1943) The blood vessels of the jejunum and ileum: a comparative study of man and certain laboratory animals. *Amer J Anat* **73**: 293-334.
- Obach RS, Lombardo F and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. *Drug Metab Dispos* **36**: 1385-1405.
- Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of *in vitro* half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* **27**:1350-1359.
- Oberle RL, Das H, Wong SL, Chan KK and Sawchuk RJ (1994) Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. *Pharm Res* **11**: 698-703.
- Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C and Landsiedel R (2007) Drug-metabolizing enzymes in the skin of man, rat and pig. *Drug Metab Rev* **39**: 659-698.
- van Peer E, Verbueken E, Saad M, Casteleyn C, van Ginneken C and van Cruchten S (2014) Ontogeny of CYP3A and P-glycoprotein in the liver and the small intestine of the Göttingen minipig: an immunohistochemical evaluation. *Basic Clin Pharmacol Toxicol* **114**: 387-394.
- Paudel K, Milewski M, Swadley C, Brogden N, Priyanka, Ghosh P, and Stinchcomb A. (2010). Challenges and opportunities in dermal/transdermal delivery. *Ther Deliv*. **1**: 109–131.

- Pershing L, Huether S, Conklin R, Krueger G. (1989) Cutaneous blood flow and percutaneous absorption: a quantitative analysis using a laser Doppler velocimeter and a blood flow meter. *J Invest Dermatol*. **92**:355-9.
- Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L and Lennernas H (2006) First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. *Drug Metab Dispos* **34**: 1182-1189.
- Pond WG and Mersmann HJ (2001) *Biology of the Domestic Pig*. Cornell University Press, Ithaca, NY.
- Porter V (1993) *Pigs, a Handbook of the Breeds of the World*. Cornell University Press, Ithaca, NY
- Poulin P (2013) Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the *in vitro-in vivo* extrapolation methods: emphasis on apparent fraction unbound in liver for drugs. *J Pharm Sci* **102**: 2085-2095.
- Poulin P and Haddad S (2018) Extrapolation of the hepatic clearance of drugs in the absence of albumin *in vitro* to that in the presence of albumin *in vivo*: comparative assessment of 2 extrapolation models based on the albumin-mediated hepatic uptake theory and limitations and mechanistic insights. *J Pharm Sci* **107**: 1-7.
- Preube C and Skaanild MT (2012) Minipigs in absorption, distribution, metabolism, and excretion (ADME) studies, in *The Minipig in Biomedical Research* (McAnulty PA, Dayan AD, Ganderup N-C and Hastings KL, eds.) p. 145. CRC Press, Boca Raton, FL.

- Priborsky J and Muhlbachova E. (1990) Evaluation of *in-vitro* percutaneous absorption across human skin and in animal models. *J Pharm Pharmacol.* **42**:468–72.
- Prusakiewicz JJ, Ackerman C and Voorman R (2006) Comparison of skin esterase activities from different species. *Pharm Res* **23**: 1517-1524.
- Puccinelli E, Gervasi PG and Longo V (2011) Xenobiotic metabolizing cytochrome P450 in pig, a promising animal model. *Curr Drug Metab* **12**: 507-525.
- Ramsay-Olocco K, Alexandrova L, Nellore R, Killion R, Li L, Coen P, Ho Q, Jung D, Rocha C (2004) Pre-clinical and clinical evaluation of solution and soft gelatin capsule formulations for the BCS class 3 compound with atypical physiochemical properties. *J Pharm Sci* **93**: 2214-2221.
- Rangarajan and Zatz (2001). Effect of formulation on the delivery and metabolism of alphanatocopheryl acetate. *J. Cosmet. Sci.* **52**:225–236.
- Riede J, Poller B, Umehara K, Huwyler J and Camenisch G (2016) New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from *in vitro* hepatocyte and microsome data. *Eur J Pharm Sci* **30**: 96-102.
- Ring BJ, Chien JY, Adkinson KK, Jones HM, Rowland M, Jones RD *et al.* (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3. Comparative assessment of prediction methods of human clearance. *J Pharm Sci* **100**: 4090-4110.
- Rohatagi S, Barrett JS, McDonald LJ, Morris EM, Darnow J, DiSanto AR. (1997) Selegiline percutaneous absorption in various species and metabolism by human skin. *Pharm Res.* **14**:50-5.

- Rostami-Hodjegan A (2018) Reverse translation in PBPK and QSP: going backwards in order to go forward with confidence. *Clin Pharmacol Ther* **103**:224-232.
- Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of *in vivo* drug metabolism in human populations from *in vitro* data. *Nature Rev Drug Discov* **6**: 140-148.
- Rowland M, Peck C and tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. *Ann Rev Pharmacol Toxicol* **51**: 45-73.
- Sachs DH (1994) The pig as a potential xenograft donor. *Vet Immunol Immunopathol* **43**: 185-191.
- Schuurman H-J, Graham ML, Spizzo T and Patience C (2012) Xenotransplantation, in *The Minipig in Biomedical Research* (McAnulty PA, Dayan AD, Ganderup N-C and Hastings KL, eds.), pp 373-386, CRC Press, Boca Raton, FL.
- Shida S and Yamazaki H (2016) Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. *Xenobioica* **46**: 759-764.
- Shulman RF, Henning SJ and Nichols BL (1988) The miniature pig as an animal model for the study of intestinal enzyme development. *Pediatr Res* **23**: 311-315.
- Sjögren E, Bredberg U and Lennernas H (2012) The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. *Mol Pharm* **9**: 823-841.
- Skaanild MT (2006) Porcine cytochrome P450 and metabolism. *Curr Pharmaceut Design* **12**: 1421-1427.
- Skaanild MT and Friis C (1997) Characterization of the P450 system in Goettingen

- minipigs. *Pharmacol Toxicol* **80** (suppl 2): 28.
- Stricker-Krongrad A, Shoemake CR, Liu J, Brocksmith D, Bouchard G. (2017) The importance of minipigs in dermal safety assessment: an overview. *Cutan Ocul Toxicol*. **36**:105–113.
- Suenderhauf C and Parrot N (2013) A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. *Pharm Res* **30**: 1-5.
- Suenderhauf C, Tuffin G, Lorentsen H, Grimm, H-P, Flament C and Parrott N (2014) Pharmacokinetics of paracetamol in Göttingen minipigs: *In vivo* studies and modeling to elucidate physiological determinants of absorption. *Pharm Res* **31**: 2696-2707.
- Svendsen O, ed. (1998) *The Minipig in Toxicology*, Proceedings of the Satellite Symposium to Eurotox '97, Aarhus, Denmark, June 24-25, 1997. *Scand J Lab Anim Sci* **25** (Suppl 1): 1-243.
- Swindle MM (1983). *Basic Surgical Exercises Using Swine*. Praeger Press, Philadelphia, PA.
- Swindle MM (1992) *Swine as Models in Biomedical Research*, Iowa State University Press, Ames, IA.
- Swindle MM (1998) *Surgery, Anesthesia and Experimental techniques in Swine*. Iowa State University Press, Ames, IA.
- Swindle and Smith AC (1998) Comparative anatomy and physiology of the pig. *Scand J Lab Anim Sci* **25** (Suppl. 1): 11-21.
- Swindle MM (2016) Liver and biliary system, in *Swine in the Laboratory*, 3rd ed. (Swindle MM and Smith AC, eds.) pp. 135-138. CRC Press, Boca Raton, FL.

- Takeuchi H, Ishida M, Furuya A, Todo H, Urano H and Sugibayashi K (2012) Influence of skin thickness on the *in vitro* permeabilities of drugs through Sprague-Dawley rat or Yucatan micropig skin. *Biol Pharm Bull* **35**: 192-202 (2012).
- Tang H, Pak Y and Mayersohn M (2004) Protein expression pattern of P-glycoprotein along the gastrointestinal tract of the Yucatan micropig. *J Biochem Mol Toxicol* **18**: 18-22.
- Tang H and Mayersohn M (2005a) A novel model for prediction of human drug clearance by allometric scaling. *Drug Metab Dispos* **33**: 1297-1303.
- Tang H and Mayersohn M (2005b) Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. *Drug Metab Dispos* **33**: 1288-1293.
- Tang H and Mayersohn M (2005c) A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. *Drug Metab Dispos* **33**: 1294-1296.
- Tang H, Hussain A, Leal M, Mayersohn M, and Fluhler E (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. *Drug Metab Dispos* **35**: 1886-93
- Thorn HA, Lundahl A, Schrickx A, Dickinson PA and Lennernas H (2011). Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. *Eur J Pharm Sci* **43**: 89-98.
- Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. *Clin Pharmacol Ther* **59**: 491-502.

- Trepanier LA, Ray K, Winand NJ, Spielberg SP and Cribb AE (1997) Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. *Biochem Pharmacol* **54**: 73-80.
- Tumbleson ME, ed. (1986) *Swine in Biomedical Research*, vol. 1-3, Plenum Press, New York, NY.
- Tumbleson ME and Schook LB, eds. (1996) *Advances in Swine in Biomedical Research*, vol. 1-2. Plenum Press, New York, NY.
- Upton RN (2008) Organ weights and blood flows of sheep and pig for physiological pharmacokinetic modelling. *J Pharmacol Toxicol Meth* **58**: 198-205.
- Van der Laan JW, Brightwell J, McAnulty P, Ratky J and Stark C (2010). Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. *J Pharmacol Toxicol Meth* **62**: 184-195.
- Van Ginneken C (2012) Gastrointestinal tract, in *The Minipig in Biomedical Research* (McAnulty PA, Dayan AD, Ganderup N-C and Hastings KL, eds.) p. 212-213. CRC Press, Boca Raton, FL.
- Walters EM, Agca Y, Ganjam V and Evans T (2011) Animal models got you puzzled? think pig. *Ann NY Acad Sci* **1245**: 63-64.
- Waltz E (2017) When pig organs will fly. *Nature Biotechnol* **35**: 1133-1138
- Westerhout J, van de Steeg E, Grossouw D, Zeijdner EE, Krul CA, Verwei M, Wortelboer HM (2014) A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices. *Eur J Pharm Sc* **63**: 167–177
- Wilkinson DJ, Southall RL, Li M, Wright LM, Corfield LJ *et al.* (2017) Minipig and human metabolism of aldehyde oxidase substrates: *in vitro-in vivo* comparisons *AAPS J*

19: 1163-1174.

- Willis JF, Kendall MJ, Flinn RM, Thornhill DP and Welling PG (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. *Eur J Clin Pharmacol* **16**: 405-410.
- Witkamp RF and Monshouwer M (1998) Pharmacokinetics *in vivo* and *in vitro* in swine. *Scan J Lab Anim Sci* **25** (suppl 1): 45-56.
- Yamamoto S, Karashima M, Sano N, Fukushi C, Tohyama K, Arai Y, Hirabayashi H and Amano N (2017) Utility of Göttingen minipigs for prediction of human pharmacokinetic profiles after dermal drug application. *Pharm Res* **34**: 2415-2424.
- Yamazaki M, Shimizu M, Uno Y and Yamazaki H (2014) Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkey, rats and minipigs. *Biochem Pharmacol* **90**: 159165.
- Yoshimatsu H, Konno Y, Ishii K, Satsukawa M and Yamashita S (2016) Usefulness of minipigs for predicting human pharmacokinetics: prediction of distribution volume and plasma clearance. *Drug Metab Pharmacokin* **31**: 73-81.
- Yoshimatsu H, Ishii K, Konno Y, Satsukawa M and Yamashita S. (2017) Prediction of human percutaneous absorption from in vitro and in vivo animal experiments. *Int J Pharm.* **534**:348-355
- Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM Moon YJ Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Berglund EG, Lesko LJ and Huang S-M (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. *Clin Pharmacol Ther* **89**: 259-267.

Zhao DH, Zhang CY, Zhang Z, Liu ZC, Liu BT, Yu JJ, Guo JP, Deng H and Liu YH (2012)

Population pharmacokinetics of cefquinome in pigs. *J Vet Pharmacol Therap* **36**:
313-319.

Zhao DH, Zhang Z, Zhang CY, Liu ZC, Deng H, Yu JJ, Guo JP and Liu YH (2013)

Population pharmacokinetics of valnemulin in swine. *J Vet Pharmacol Therap* **37**:
59-65.

Figure legends:

Figure 1: (Left) Comparison of the fraction of the oral dose absorbed systemically (F) in humans and pigs; (Right) Comparison of the fraction of the oral dose absorbed systemically (F) in humans and non-human primates (NHP). The lines shown are the lines of identity and the 2-fold and 0.5-fold ranges. The NHP data were taken directly from the tabular data of Muster *et al.* (2014). Reproduced with permission of the copyright owner (Saguaro Technical Press, Inc.).

Figure 2: The comparison of predicted vs. observed systemic clearance (CL) in humans based on the optimized model in pigs. Lines shown are the line of identity and the ranges from 3-fold to 0.33-fold. Data compiled in Table A1 (Appendix). Reproduced with permission of the copyright owner (Saguaro Technical Press, Inc.).

Figure 3: (A): An example IVIVC study design in three Göttingen minipigs with a sequence of IV, Formulation A and Formulation B, with a one-week washout in-between dosing the groups. (B): The IVIVC analysis for one pig (Fig 1). The IV PK in Fig 1 is modeled and impulse response function is obtained. Deconvolution is conducted to estimate the *in vivo* absorption rate (r_{abs}) of Formulation A. The correlation, based on Formulation A, is modeled between *in vivo* r_{abs} in Fig 1 and *in vitro* permeability in Pig N from the minipig skin bank. The *in vitro* permeability in Pig N for Formulation B, thus, is plugged into the correlation model to estimate r_{abs} in Fig 1 of Formulation B. The next step is to use the convolution method to predict the *in vivo* transdermal PK of Formulation B based on the estimated r_{abs} in Fig 1 and the impulse response function from the IV PK. The last step is to evaluate the performance of the predicted PK vs. the observed PK with Formulation B. Reproduced with permission of the copyright owner (Saguaro Technical Press, Inc.).

Table 1: Comparison of the prediction performance of the single-species methods among rat, dog, monkey and pig. The rat, dog and monkey data were taken from Tang *et al.*, 2007. Percentage fold-error is predicted/observed.

Prediction errors	Pig	Rat	Dog	Monkey
AAFE	1.96	2.35	2.52	1.90
% fold-error out (0.5–2)	38	49	50	29
% fold-error out (0.33–3)	18	28	27	20
Coefficients	0.314	0.152	0.410	0.467




Figure 1




Figure 2




Figure 3 A and B:

Appendix:

PORCINE PREDICTION OF PHARMACOKINETIC PARAMETERS IN PEOPLE: A PIG IN A POKE?

Huadong Tang and Michael Mayersohn

Drug Metabolism and Disposition

Methods used in data collection and selection of oral bioavailability data in pigs and humans:

All of the relevant published articles about the pharmacokinetics or bioavailability of drugs in pigs were obtained from a Pubmed search. The corresponding bioavailability data of those drugs in humans were obtained in the same way. Data were considered to be comparable on the basis of experimental conditions, including drug dose, drug dosage forms, human/animal fasted/fed status, *etc.* After examining the experimental methods and conditions under which the F values were determined, 31 pairs of F data were considered for analysis (Table A1). F refers to the absolute systemic oral bioavailability; by strict definition, both systemic PK (usually from an IV dose) and oral PK are needed to calculate absolute F. A few other considerations were made when evaluating the F for comparison.

- Food status should be the same in both pig and human. For example, food dramatically affects F of Fluoride. F in both pigs and humans was reduced by about 50% when the element was taken with food. Because food used in pigs and humans could not be compared, only the F values under fasted condition in both humans and pigs were used.

- If nonlinear elimination and/or absorption were observed, the comparison was made under the most comparable dose and/or exposure between the two species
- F may be calculated using other reasonable methods. For example, bioavailability of ciprofloxacin was calculated based on urine data ($F = (X_{po} \times \text{dose}_{iv}) / (X_{iv} \times \text{dose}_{po})$) was 48% (X_u is the amount of unchanged drug excreted in the urine for oral, po, or IV, intravenous administration).
- If absorption was known (such as from urine data) and no or minimal metabolism is involved in elimination, then F could be estimated based on the absorption fraction. Doxycycline is an example of using urine data to calculate F.
- If complete absorption is verified and oral clearance is known, then F estimated by, $Q / (Q + CL_{po})$, was a reasonable method, such as for the case of levamisole (*Adams, 1978*); where Q is liver blood flow.
- If complete absorption was verified and hepatic clearance was estimated to be very low, indicating a low hepatic extraction ratio, then F was considered to be near complete and 95% F was assigned. This was the case for human F of sulphadiazine.
- If numerically F was reported over 100%, a 100% value was assigned.
- Some reported “F” values in pigs and humans were not included after
- careful examination of the reports for various reasons. Examples include:
 - In pigs, food administered differed significantly or unknown/incomparable in nature, such as for chloramphenicol, the

drug was co-administered with standard concentrate, milk or bran, which had no comparable experimental design in human studies (Bueno *et al.*, 1984).

- The AUC from intravenous dosing in humans was not available for griseofulvin, although the oral AUC/dose was comparable between pigs and humans (Aoyagi *et al.*, 1984).
- Urinary recovery of unchanged difloxacin was about 32% in humans after oral dosing, whereas in pigs, the AUC-based F was found to be 93.7% (Inui *et al.*, 1998; Granneman *et al.*, 1986).
- The plasma concentrations of quercetin after oral dosing in humans could not be detected, therefore, the F value for humans is not available (Ader *et al.*, 2000; Hollman *et al.*, 1995). The available data did not represent parent drug absorption and were considered unusable.
- Simultaneous dosing of five compounds (caffeine, warfarin, omeprazole, metoprolol and midazolam), which were dissolved and dosed in 10% w/v WellSolve at 1.0 mg/kg, were not included (Mogi *et al.*, 2012). The total dose, combining five compounds, was actually 5 mg/kg. Comparing to solid dosage forms used in a human study, such oral dosages and forms may not be comparable. Potential precipitations in GI tract and potential interactions may occur as well. Midazolam F in pigs was only about 3%, comparing to ~12% in the

other study (Lignet *et al.*, 2016), raising the question of compatibility of this pig study to the studies in humans.

Table A1: Oral bioavailability values in pigs and humans.

Drugs	Breeds	F _{pig}	F _{human}	References
amoxycillin	Danish L-RxDurocYorkshire	33	65	Agerso <i>et al.</i> , 1998; Paintaud <i>et al.</i> , 1992
acetaminophen	Seghers Hybrid, Belgium	75.5	87	Rawlins <i>et al.</i> , 1977; Neirinckx <i>et al.</i> , 2010; Ameer, <i>et al.</i> , 1983
antipyrine	Göttingen Minipig	36	91	Vickers <i>et al.</i> , 1989; Lignet <i>et al.</i> , 2016; Rimmer <i>et al.</i> , 1986
chlortetracycline	Chester WhitexYorkshire	15	30	Nielsen <i>et al.</i> , 1996; Kilrol <i>et al.</i> , 1990; Fabre <i>et al.</i> , 1971
cimetidine	Göttingen Minipig	33	78	Lignet <i>et al.</i> , 2016; Obach, <i>et al.</i> , 2008
ciprofloxacin	NA	37.3	48	Nouws <i>et al.</i> , 1988; Plaisance <i>et al.</i> 1987; Chukwuani <i>et al.</i> , 2000
cyclosporine	L-R	58	60	Mueller <i>et al.</i> , 1994; Primmatt <i>et al.</i> , 1998; Keohane <i>et al.</i> , 2016
diclofenac	Yucatan miniature	100	42	Oberle <i>et al.</i> , 1994; Willis <i>et al.</i> , 1979
doxycycline	Conventional pig	100	95	Pijpers <i>et al.</i> , 1994; Saivin <i>et al.</i> , 1988
fenofibrate	L-R	71	69	Zhu <i>et al.</i> , 2010; McCarthy <i>et al.</i> , 2017; Sauron <i>et al.</i> , 2006
finasteride	mixed breed (Hampshire, Yorkshire, and Swedish L-R	40	80	Lundahl <i>et al.</i> , 2011; Obach <i>et al.</i> , 2008
fluoride	Danish landrace	54.5	100	Richards <i>et al.</i> , 1982; Ekstrand <i>et al.</i> , 1979
hydrochlorothiazide	Göttingen Minipig	62	72	Sietsema 1989;

				Lignet <i>et al.</i> , 2016; Obach <i>et al.</i> , 2008
ketoprofen	L-R	86	85	Jamali and Brocks, 1990; Geisslinger <i>et al.</i> , 1995; Neirinckx <i>et al.</i> , 2011
levamisole	Large-White	62	62.5	Watson <i>et al.</i> , 1988; Galtier <i>et al.</i> , 1983; Kouassi <i>et al.</i> , 1986
lincomycin	NA	73	63	Nielsen <i>et al.</i> , 1998; Simon <i>et al.</i> , 1976
lovastatin	Bama	4.97	5	Liu <i>et al.</i> , 2008; Obach <i>et al.</i> , 2008
meloxicam	Cross-bred Newsham cull sows	87	89	Turck <i>et al.</i> , 1997; Pairis-Garcia <i>et al.</i> , 2014
midazolam	Göttingen Minipig	12	34	Allonen <i>et al.</i> , 1981; Lignet <i>et al.</i> , 2016
moxifloxacin	Göttingen Minipig	54	82	Siefert <i>et al.</i> , 1999
naproxen	Danish landxYork shire	91.6	74	Runkel <i>et al.</i> , 1972
oxytetracycline	NA	6	58	Nielsen and Gyrð- Hansen, 1996; Fabre <i>et al.</i> , 1971
pencillin V	NA	18.9	32	Nielsen and Gyrð- Hansen, 1994b; Bauer <i>et al.</i> , 1989
spiramycin	Swiss L-R	45.4	36	Sutter <i>et al.</i> , 1992; Frydman <i>et al.</i> 1988
sulfisoxazole	NA	100	100	Suber <i>et al.</i> , 1981; Kaplan <i>et al.</i> , 1972
sulphadiazine	NA	89	95	Nielsen and Gyrð- Hansen, 1994a; Reeves <i>et al.</i> , 1979
tetracycline	Chester WhitexYorkshire	20.5	77	Kniffen <i>et al.</i> , 1989; Nielsen and Gyrð- Hansen, 1996; Fabre <i>et al.</i> , 1971
theophylline	Yorkshire	79	100	Tse <i>et al.</i> , 1982; Koritz, <i>et al.</i> , 1981; Boner <i>et al.</i> , 1987
trimethoprim	NA	90	100	Nielsen and Gyrð- Hansen, 1994; Chin <i>et al.</i> , 1995
vigabatrin	Göttingen Minipig	75	85	Nohr MK <i>et al.</i> , 2014;

Table A2: Systemic clearance (CL) values in pigs and humans

Drugs	Pig CL mL/min·kg	Human CL mL/min·kg	References
antipyrine	3.15	0.600	Lignet <i>et al.</i> , 2016
atenolol	7.95	1.00	Lignet <i>et al.</i> , 2016
cimetidine	37.4	8.30	Lignet <i>et al.</i> , 2016
diazepam	9.60	0.400	Lignet <i>et al.</i> , 2016
hydrochlorothiazide	11.8	3.00	Lignet <i>et al.</i> , 2016
midazolam	22.3	5.20	Lignet <i>et al.</i> , 2016
theophylline	1.15	0.800	Lignet <i>et al.</i> , 2016
acetaminophen	3.18	5.00	Yoshimatsu <i>et al.</i> , 2016
antipyrine	3.94	0.640	Yoshimatsu <i>et al.</i> , 2016
atenolol	3.52	2.50	Yoshimatsu <i>et al.</i> , 2016
buprenorphine	17.1	18.9	Yoshimatsu <i>et al.</i> , 2016
diclofenac	1.20	3.50	Yoshimatsu <i>et al.</i> , 2016
felodipine	14.5	11.0	Yoshimatsu <i>et al.</i> , 2016
fentanyl	20.5	19.0	Yoshimatsu <i>et al.</i> , 2016
fexofenadine	4.74	3.10	Yoshimatsu <i>et al.</i> , 2016
flurbiprofen	0.790	0.300	Yoshimatsu <i>et al.</i> , 2016
furosemide	5.75	1.60	Yoshimatsu <i>et al.</i> , 2016
ketoprofen	0.913	1.14	Yoshimatsu <i>et al.</i> , 2016
lidocaine	12.8	13.6	Yoshimatsu <i>et al.</i> , 2016
propranolol	11.1	12.0	Yoshimatsu <i>et al.</i> , 2016
raloxifene	21.5	10.8	Yoshimatsu <i>et al.</i> , 2016
caffeine	0.966	1.40	Mogi <i>et al.</i> , 2012
warfarin	0.139	0.055	Mogi <i>et al.</i> , 2012
omeprazole	8.44	8.40	Mogi <i>et al.</i> , 2012
metoprolol	26.7	13.0	Mogi <i>et al.</i> , 2012
midazolam	13.9	5.30	Mogi <i>et al.</i> , 2012
finasteride	7.00	2.40	Lundahl <i>et al.</i> , 2011 Steiner 1996
amoxycillin	9.67	3.30	Reyns, 2007; Obach <i>et al.</i> , 2008
ciprofloxacin	17.5	8.30	Nouws <i>et al.</i> , 1988; Obach <i>et al.</i> , 2008
doxycycline	1.67	0.460	Zhang <i>et al.</i> , 2018; Obach <i>et al.</i> , 2008
lincomycin	6.83	2.10	Kurohad, <i>et al.</i> , 2001
moxifloxacin	10.8	2.40	Siefert <i>et al.</i> , 1999; Obach <i>et al.</i> , 2008

tetracycline	3.08	1.50	Nielson and Gyrd-Hansen, 1996; Obach <i>et al.</i> , 2008
sulphadiazine	2.33	0.550	Nielson and Gyrd-Hansen, 1994; Obach <i>et al.</i> , 2008
sulfisoxazole	4.41	0.300	Obach <i>et al.</i> , 2008; Suber <i>et al.</i> , 1981;
trimethoprim	9.17	2.10	Nielson and Gyrd-Hansen, 1994; Obach <i>et al.</i> , 2008
cyclosporine	8.95	7.50	Vaden and Riviere, 1990; Obach <i>et al.</i> , 2008
ketamine	48.1	19.0	In-house
meloxicam	0.718	0.120	Pairis-Garcia <i>et al.</i> , 2014; Obach <i>et al.</i> , 2008
lovastatin	22.6	7.20	Liu <i>et al.</i> , 2008; Obach <i>et al.</i> , 2008

References for Appendix Table A1 (oral bioavailability in pigs and humans):

- Adams JG (1978) Pharmacokinetics of levamisole. *J Rheumatol Suppl* **4**: 137-142.
- Ader P, Wessmann A, and Wolfram S (2000) Bioavailability and metabolism of the flavanol quercetin in the pig. *Free Radic Biol Med* **2**: 1056-1067.
- Agerso H and Friis C (1998) Bioavailability of amoxycillin in pigs. *J Vet Pharmacol Ther* **21**: 41-46.
- Allonen H, Ziegler G, Klotz U. (1981) Midazolam *kinetics Clin Pharmacol Ther* **5**: 653–661
- Ameer B, Divoll M, Abernethy DR, Greenblatt DJ and Shargel L (1983) Absolute and relative bioavailability of oral acetaminophen preparations. *J Pharm Sci* **72**: 955-958.
- Aoyagi N, Ogata H, Kaniwa N, Ejima A, Yasud Y and Tanioka Y (1984) Bioavailability of griseofulvin from plain tablets in Göttingen minipigs and the correlation with bioavailability in humans. *J Pharmacobiodyn* **7**: 7-14.
- Bauer B, Malerczyk V and Roethig HJ (1989) Bioavailability of a new liquid formulation of penicillin V (Isocillin syrup) and the influence of ethanol on bioavailability of penicillin V. *Int Clin Pharmacol Ther Toxicol* **27**: 583-587.
- Boner AL, De Stefano G, Vallone G, Plebani M and Ventura P (1987) Absolute and relative bioavailability of a slow release theophylline preparation in asthmatic children. *J Int Med Res* **15**: 282-292.
- Bueno, L.; Fioramonti, J.; Alvinerie, M.; Bardon, T. (1984) Influence of bran on bioavailability of chloramphenicol administered orally to pigs. *Can. J. Physiol Pharmacol.* **62**: 208-211.

- Chin, T. W.; Vandenbroucke, A.; Fong, I. W. (1995) Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. *Antimicrob. Agents Chemother.* **39**: 28-33.
- Chukwuani, C. M.; Coker, H. A.; Oduola, A. M.; Sowunmi, A.; Ifudu, N. D. (2000) Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. *Biol. Pharm. Bull.* **23**: 968-972.
- Ekstrand, J.; Ehrnebo, M. (1979) Influence of milk products on fluoride bioavailability in man. *Eur. J. Clin. Pharmacol.* **16**: 211-215.
- Fabre, J.; Milek, E.; Kalfopoulos, P.; Merier, G. (1971) Tetracycline kinetics in man. Digestive absorption and serum concentration. *Schweiz. Med. Wochenschr.* **101**: 593-598.
- Frydman, A. M.; Le Roux, Y.; Desnottes, J. F.; Kaplan, P.; Djebbar, F.; Cournot, A.; Duchier, J.; Gaillot, J. (1988) Pharmacokinetics of spiramycin in man. *J. Antimicrob. Chemother.* **22 Suppl B**: 93-103.
- Galtier, P.; Escoula, L.; Alvinerie, M. (1983) Pharmacokinetics of [3H]levamisole in pigs after oral and intramuscular administration. *Am. J. Vet. Res.* **44**: 583-587.
- Geisslinger G et al. Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. (1995) *Br J Clin Pharmacol* **1**: 73–75.
- Granneman, G. R.; Snyder, K. M.; Shu, V. S. (1986) Difloxacin metabolism and pharmacokinetics in humans after single oral doses. *Antimicrob. Agents Chemother.* **30**, 689-693.

- Inui, T.; Taira, T.; Matsushita, T.; Endo, T. (1998) Pharmacokinetic properties and oral bioavailabilities of difloxacin in pig and chicken. *Xenobiotica* **28**, 887-893
- Jamali F and Brocks D.R. (1990) Clinical pharmacokinetics of ketoprofen and its enantiomers. *Clin Pharmacokinet*, **19**: 197-217
- Kaplan, S. A.; Weinfeld, R. E.; Abruzzo, C. W.; Lewis, M. (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man. *J. Pharm. Sci.* **61**: 773-778.
- Koritz, G. D.; Bourne, D. W.; Hunt, J. P.; Prasad, V. I.; Bevill, R. F.; Gautam, S. R. (1981) Pharmacokinetics of theophylline in swine: a potential model for human drug bioavailability studies. *J. Vet. Pharmacol. Ther.* **4**: 233-239.
- Kniffen, T. S.; Bane, D. P.; Hall, W. F.; Koritz, G. D.; Bevill, R. F. (1989) Bioavailability, pharmacokinetics, and plasma concentration of tetracycline hydrochloride fed to swine. *Am. J. Vet. Res.* **50**: 518-521.
- Kouassi, E.; Caille, G.; Lery, L.; Lariviere, L.; Vezina, M. (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. *Biopharm. Drug Dispos.* **7**: 71-89.
- Lignet F, Sherbetjian E, Kratochwil N, Jones R, Suenderhauf C, Ottender MB, Singer T and Parrott N (2016) Characterization of pharmacokinetics in the Göttingen minipig with reference human drugs: an in vitro and in vivo approach. *Pharm Res* **33**: 2565-2579.
- Liu, Zeng, Shang, Cen, and Wei. (2008) Bama Miniature Pigs (*Sus scrofa domestica*) as a Model for Drug Evaluation for Humans: Comparison of *In Vitro* Metabolism and In Vivo Pharmacokinetics of Lovastatin *Comparative Medicine* **58**, 580–587

- Lundahl A, Hedeland M, Bondesson U, Lennernäs H. (2011) In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5 α -reductase inhibitor finasteride and the effects of coadministered ketoconazole. *Drug Metab Dispos.* **39**: 847-57.
- Mogi M, Toda A, Iwasaki K, Kusumoto S, Takehara H, Shimizu M, Murayama N, Izumi H, Utoh M, Yamazaki H. (2012) Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to microminipigs. *J Toxicol Sci* **37**: 1157-1164.
- Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. (1994) Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. *Pharm Res* **2**: 301–304.
- Neirinckx E, Croubels S, De Boever S, Remon JP, Bosmans T, Daminet S, De Backer P, Vervaeke C (2011) Species comparison of enantioselective oral bioavailability and pharmacokinetics of ketoprofen. *Res Vet Sci* **3**: 415–421.
- Nielsen, P.; Gyrd-Hansen, N. (1996) Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. *J. Vet. Pharmacol. Ther.* **19**: 305-311.
- Nielsen, P.; Gyrd-Hansen, N. (1994a) Oral bioavailability of sulphadiazine and trimethoprim in fed and fasted pigs. *Res. Vet. Sci.* **56**: 48-52.
- Nielsen, P.; Gyrd-Hansen, N. (1994b) Bioavailability of penicillin V after oral administration to fed and fasted pigs. *J. Vet. Pharmacol. Ther.* **17**: 160-162.
- Nielsen, P.; Gyrd-Hansen, N. (1998) Bioavailability of spiramycin and lincomycin after oral administration to fed and fasted pigs. *J. Vet. Pharmacol. Ther.* **21**: 251-256.

- Nøhr MK, Thale Z, B, Hansen S, Holm R and Nielsen C (2014) Intestinal absorption of the antiepileptic drug substance vigabatrin in Gottingen mini-pigs is unaffected by co-administration of amino acids. *Pharmacol Res Perspect.* **2**: 1-11
- Nouws, J. F.; Mevius, D. J.; Vree, T. B.; Baars, A. M.; Laurensen, J. (1998) Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. *Vet. Q.* **10**: 156-163.
- Obach RS, Lombardo F and Waters NJ. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. *Drug Metab Dispos* **36**: 1385-1405.
- Oberle, R. L.; Das, H.; Wong, S. L.; Chan, K. K.; Sawchuk, R. J. (1994) Pharmacokinetics and metabolism of diclofenac sodium in Yucatan miniature pigs. *Pharm. Res.* **11**: 698-703.
- Paintaud, G.; Alvan, G.; Dahl, M. L.; Grahnen, A.; Sjøvall, J.; Svensson, J. O. (1992) Nonlinearity of amoxicillin absorption kinetics in human. *Eur. J. Clin. Pharmacol.* **43**; 283-288.
- Pairis-Garcia MD, Johnson AK, KuKanich B, Wulf L, Millman ST, Stalder KJ, Karriker LA, Coetzee JF. (2014) Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration *J. Vet. Pharmacol. Therap.* **38**: 265--270
- Pijpers A., Schoevers E.J., Swinkels J., Postma G., Verenooy J.C.M., and Verheijhem J.H.M. (1994) *Proceedings of the 6th EAVPT Congress.* 42-43.
- Plaisance, K. I.; Drusano, G. L.; Forrest, A.; Bustamante, C. I.; Standiford, H. C. (1987) Effect of dose size on bioavailability of ciprofloxacin. *Antimicrob. Agents Chemother.* **31**: 956-958.

- Primmatt DR, Levine M, Kovarik JM, Mueller EA, Keown PA. (1998) Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. *Ther Drug Monit* **3**: 276–283.
- Rawlins, M. D.; Henderson, D. B.; Hijab, A. R. (1977) Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. *Eur J Clin Pharmacol* **11**: 283-286
- Reeves, D. S.; Broughall, J. M.; Bywater, M. J.; Holt, H. A.; Vergin, H. (1979) Pharmacokinetics of tetroxoprim and sulphadiazine in human volunteers. *J. Antimicrob. Chemother.* **5**: 119-138.
- Rimmer, E. M.; Routledge, P. A.; Tsanaclis, L. M.; Richens, A. (1986) Pharmacokinetics of antipyrine in epileptic patients. *Br. J Clin Pharmacol* **21**: 511-514.
- Richards, A.; Fejerskov, O.; Ekstrand, J. (1982) Fluoride pharmacokinetics in the domestic pig. *J. Dent. Res.* **61**: 1099-1102.
- Runkel, R.; Chaplin, M.; Boost, G.; Segre, E.; Forchielli, E. (1972) Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. *J. Pharm. Sci.* **61**: 703-708.
- Saivin, S.; Houin, G. (1988) Clinical pharmacokinetics of doxycycline and minocycline. *Clin. Pharmacokinet.* **15**: 355-366.
- Sietsema WK. The absolute oral bioavailability of selected drugs. (1989) *Int J Clin Pharmacol Ther Toxicol* **4**: 179–211

- Siefert, H. M.; Domdey-Bette, A.; Henninger, K.; Hücke, F.; Kohlsdorfer, C.; Stass, H. H. (1999) Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. *J. Antimicrob. Chemother.* **43 Suppl B**: 69-76.
- Simon, C.; Malerczyk, V.; Eidelloth, E. (1976) Pharmacokinetics of lincomycin and clindamycin. *Med. Welt.* **27**: 1096-1100.
- Suber, R. L.; Lee, C.; Torosian, G.; Edds, G. T. (1981) Pharmacokinetics of sulfisoxazole compared in humans and two monogastric animal species. *J. Pharm. Sci.* **70**: 981-984.
- Sutter, H. M.; Engeli, J.; Müller, P.; Schneider, B.; Riond, J. L.; Warner, M. (1992) Pharmacokinetics and bioavailability of spiramycin in pigs. *Vet. Rec.* **130**: 510-513.
- Tse, F. L. and Szeto, D. W. (1982) Theophylline bioavailability in the dog. *J Pharm. Sci.* **71**: 1301-1303.
- Türk D, Busch U, Heinzl G, Narjes H. (1997) Clinical pharmacokinetics of meloxicam. *Arzneimittelforschung.* **47**: 253-8.
- Vickers, F. F.; Bowman, T. A.; Dvorchik, B. H.; Passananti, G. T.; Hughes, D. M.; Vesell, E. S. (1989) On the antipyrine test in laboratory animals. Studies in the dog and monkey. *Drug Metab Dispos.* **17**: 160-165.
- Watson, A. D.; Sangster, N. C.; Church, D. B.; van Gogh, H. (1988) Levamisole pharmacokinetics and bioavailability in dogs. *Res Vet Sci.* **45**: 411-413.

Willis, J. V.; Kendall, M. J.; Flinn, R. M.; Thornhill, D. P.; Welling, P. G. (1979) The pharmacokinetics of diclofenac sodium following intravenous and oral administration. *Eur. J. Clin. Pharmacol.* **16**: 405-410.

Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. (2010) Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. *J Clin Pharmacol* **8**: 914–921.